gene_name	drug_name	interaction_type	source	gene_categories
FLT3	SORAFENIB	antagonist	DrugBank	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SUNITINIB	multitarget	DrugBank	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	inhibitor	DrugBank	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	NINTEDANIB	inhibitor	DrugBank	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SUNITINIB	n/a	TEND	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	TEND	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	TANDUTINIB	inhibitor	TTD	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SU5614	inhibitor	TTD	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	TANDUTINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	AMUVATINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CABOZANTINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SUNITINIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	AMUVATINIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB TOSYLATE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	BORTEZOMIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CLOFARABINE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB TOSYLATE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SUNITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CEDIRANIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	DOVITINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	FLT-3 INHIBITOR	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	FLT-3 INHIBITOR II	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	FLT-3 INHIBITOR III	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	GTP-14564	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LINIFANIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PACRITINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	RGB-286638	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	4SC-202	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LINIFANIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	ENMD-2076	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	AMUVATINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SUNITINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	TANDUTINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB TOSYLATE	inhibitor	ChEMBL	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SUNITINIB MALATE	inhibitor	ChEMBL	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	DAUNORUBICIN	n/a	CIViC	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	CIViC	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
EGFR	LIDOCAINE	antagonist	DrugBank	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	antagonist	DrugBank	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	antagonist	DrugBank	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	VANDETANIB	inhibitor	DrugBank	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AFATINIB	inhibitor	DrugBank	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	CI-1033	n/a	DrugBank	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE	n/a	DrugBank	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	n/a	PharmGKB	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GELDANAMYCIN	n/a	PharmGKB	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	n/a	PharmGKB	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	n/a	TEND	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	n/a	TEND	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB	n/a	TEND	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	TAK165	inhibitor	TTD	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	BIBW 2992	inhibitor	TTD	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	VANDETANIB	inhibitor	TTD	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	TTD	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AZD4769	inhibitor	TTD	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	inhibitor	TTD	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	n/a	ClearityFoundationBiomarkers	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	VANDETANIB	n/a	ClearityFoundationBiomarkers	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	n/a	ClearityFoundationBiomarkers	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	VANDETANIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AFATINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	CO-1686	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AZD8931	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	BMS-599626	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	PELITINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	DACOMITINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	inhibitor	CancerCommons	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB	inhibitor	CancerCommons	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	MOMELOTINIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	BMS-599626	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	VANDETANIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AEE 788	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	CUDC-101	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AFATINIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	NERATINIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	PELITINIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	DACOMITINIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	BMS-690514	inhibitor	TALC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	n/a	ClearityFoundationClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AKOS004227608	n/a	ClearityFoundationClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AKOS004227608	n/a	ClearityFoundationClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB	n/a	ClearityFoundationClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB	n/a	ClearityFoundationClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	VANDETANIB	n/a	ClearityFoundationClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AP26113	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB DITOSYLATE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB DITOSYLATE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AP26113	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AP26113	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB DITOSYLATE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	DACOMITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AP26113	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	DACOMITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB DITOSYLATE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AFATINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	VANDETANIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AFATINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AFATINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	DACOMITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	POZIOTINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	DACOMITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	DACOMITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB DITOSYLATE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AP26113	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AP26113	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AP26113	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AP26113	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AFATINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AP26113	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	BMS-599626	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	BPIQ-I	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	DACOMITINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	EGFR INHIBITOR	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	FALNIDAMOL	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ICOTINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	NERATINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	PD 158780	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	PD 174265	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	PELITINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AFATINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	CUDC-101	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	NERATINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	DACOMITINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LIDOCAINE	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	VANDETANIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB HYDROCHLORIDE	inhibitor	ChEMBL	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	inhibitor	ChEMBL	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB DITOSYLATE	inhibitor	ChEMBL	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AFATINIB DIMALEATE	inhibitor	ChEMBL	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	EGFR INHIBITOR	n/a	CIViC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	n/a	CIViC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	n/a	CIViC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	AFATINIB	n/a	CIViC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	DACOMITINIB	n/a	CIViC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	CRIZOTINIB	n/a	CIViC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	CISPLATINUM	n/a	CIViC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	PACLITAXEL	n/a	CIViC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	CARBOPLATIN	n/a	CIViC	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	LAPATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	ERLOTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	GEFITINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
EGFR	SIROLIMUS	n/a	DoCM	cell surface,clinically actionable,druggable genome,kinase,serine threonine kinase,tumor suppressor,tyrosine kinase
gene_name	drug_name	interaction_type	source	gene_categories
FLT3	SORAFENIB	antagonist	DrugBank	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SUNITINIB	multitarget	DrugBank	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	inhibitor	DrugBank	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	NINTEDANIB	inhibitor	DrugBank	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SUNITINIB	n/a	TEND	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	TEND	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	TANDUTINIB	inhibitor	TTD	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SU5614	inhibitor	TTD	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	TANDUTINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	AMUVATINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CABOZANTINIB	inhibitor	MyCancerGenome	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SUNITINIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	AMUVATINIB	inhibitor	TALC	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB TOSYLATE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	BORTEZOMIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CLOFARABINE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB TOSYLATE	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SUNITINIB	inhibitor	MyCancerGenomeClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CEDIRANIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	DOVITINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	FLT-3 INHIBITOR	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	FLT-3 INHIBITOR II	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	FLT-3 INHIBITOR III	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	GTP-14564	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LINIFANIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PACRITINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	RGB-286638	n/a	GuideToPharmacologyInteractions	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	4SC-202	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LINIFANIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	ENMD-2076	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	AMUVATINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SUNITINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	TANDUTINIB	n/a	TdgClinicalTrial	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB TOSYLATE	inhibitor	ChEMBL	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SUNITINIB MALATE	inhibitor	ChEMBL	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	DAUNORUBICIN	n/a	CIViC	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	CIViC	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	CRENOLANIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	LESTAURTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	MIDOSTAURIN	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	QUIZARTINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	SORAFENIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
FLT3	PONATINIB	n/a	DoCM	cell surface,clinically actionable,druggable genome,external side of plasma membrane,kinase,tyrosine kinase
Unmatched search term: ABCD
Possible suggestions: 
gene_name	drug_name	interaction_type	source	gene_categories
IL6	VX-702	n/a	DrugBank	cell surface,drug resistance,external side of plasma membrane,growth factor
IL6	VX-702	n/a	DrugBank	cell surface,drug resistance,external side of plasma membrane,growth factor
PTGS2	IBUPROFEN	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	PHENYLBUTAZONE	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	MELOXICAM	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	ROFECOXIB	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	ETORICOXIB	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	TIAPROFENIC ACID	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	LUMIRACOXIB	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	DIFLUNISAL	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	ETODOLAC	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	TENOXICAM	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	NIFLUMIC ACID	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	PIROXICAM	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	MEFENAMIC ACID	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	NIMESULIDE	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	NAPROXEN	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	GW-406381	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	CARPROFEN	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	VALDECOXIB	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	NABUMETONE	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	TOLMETIN	inhibitor	TTD	drug resistance,druggable genome,tumor suppressor
PTGS2	DICLOFENAC	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	MELOXICAM	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	NIMESULIDE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	VALDECOXIB	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOROLAC	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	ASPIRIN	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	VALDECOXIB	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	SUPROFEN	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	CELECOXIB	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	MECLOFENAMIC ACID	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	ROFECOXIB	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	ETORICOXIB	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	LUMIRACOXIB	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	MEFENAMIC ACID	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOPROFEN	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	BENZQUINAMIDE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	ETODOLAC	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	CARPROFEN	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	NAPROXEN	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	IBUPROFEN	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	OXAPROZIN	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	PHENYLBUTAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	PIROXICAM	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOROLAC	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	FLURBIPROFEN	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,tumor suppressor
PTGS2	ROFECOXIB	n/a	PharmGKB	drug resistance,druggable genome,tumor suppressor
PTGS2	NIMESULIDE	n/a	PharmGKB	drug resistance,druggable genome,tumor suppressor
PTGS2	CAPECITABINE	n/a	PharmGKB	drug resistance,druggable genome,tumor suppressor
PTGS2	ETORICOXIB	n/a	PharmGKB	drug resistance,druggable genome,tumor suppressor
PTGS2	VALDECOXIB	n/a	PharmGKB	drug resistance,druggable genome,tumor suppressor
PTGS2	ETORICOXIB	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	FENOPROFEN	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOROLAC	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	ASPIRIN	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	SULINDAC	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	INDOMETHACIN	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOPROFEN	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	PHENYLBUTAZONE	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	OXAPROZIN	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	TOLMETIN	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	NAPROXEN	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	TIAPROFENIC ACID	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	MECLOFENAMIC ACID	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	DIFLUNISAL	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	FLURBIPROFEN	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	NEPAFENAC	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	NABUMETONE	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	MELOXICAM	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	IBUPROFEN	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	SUPROFEN	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	TENOXICAM	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	ACETAMINOPHEN	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	MEFENAMIC ACID	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	SALSALATE	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	SALICYLIC ACID	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	CARPROFEN	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	DICLOFENAC	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	BROMFENAC	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	ETODOLAC	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	LUMIRACOXIB	n/a	TEND	drug resistance,druggable genome,tumor suppressor
PTGS2	MECLOFENAMIC ACID	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	MEFENAMIC ACID	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	PIROXICAM	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	DIFLUNISAL	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	TENOXICAM	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	NAPROXEN ETEMESIL	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	ETORICOXIB	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	SALSALATE	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	NIFLUMIC ACID	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	NAPROXEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	NAPROXEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	APRICOXIB	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	SUPROFEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	DICLOFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	MELOXICAM	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	BROMFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	PARECOXIB	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	NAPROXCINOD	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	LUMIRACOXIB	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	NAPROXEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	NAPROXEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	ETODOLAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	BALSALAZIDE	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	SULFASALAZINE	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOPROFEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	PHENYLBUTAZONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	CARPROFEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	LICOFELONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	DICLOFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	DICLOFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	OXAPROZIN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	FENOPROFEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOPROFEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOPROFEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	CIMICOXIB	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	TOLMETIN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	DICLOFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	DICLOFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	TIAPROFENIC ACID	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	ACETAMINOPHEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	FLURBIPROFEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOROLAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOROLAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	DICLOFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	DICLOFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	DICLOFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	NABUMETONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	ETODOLAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	BROMFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	BROMFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	CELECOXIB	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOPROFEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	THALIDOMIDE	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOROLAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	SULINDAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	SALICYLIC ACID	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	ROFECOXIB	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	DICLOFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	IBUPROFEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	NEPAFENAC	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOPROFEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,tumor suppressor
PTGS2	THALIDOMIDE	antagonist	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	SULFASALAZINE	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	LICOFELONE	n/a	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	FLUFENAMIC ACID	n/a	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	MELOXICAM	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	NABUMETONE	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	ROFECOXIB	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	LENALIDOMIDE	negative modulator	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	POMALIDOMIDE	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	PROSTAGLANDIN G2	n/a	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	TRISALICYLATE-CHOLINE	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	SUPROFEN	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	PIROXICAM	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	NIFLUMIC ACID	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	ACETAMINOPHEN	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	TIAPROFENIC ACID	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	SALSALATE	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	BALSALAZIDE	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	INDOMETHACIN	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	SALICYLIC ACID	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	MECLOFENAMIC ACID	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	VALDECOXIB	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	RESVERATROL	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	LUMIRACOXIB	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOPROFEN	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	DICLOFENAC	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	TENOXICAM	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	NAPROXEN	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	ANTRAFENINE	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	MEFENAMIC ACID	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	LORNOXICAM	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	CARPROFEN	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	CELECOXIB	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	BROMFENAC	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	IBUPROFEN	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	KETOROLAC	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	ETORICOXIB	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	CIMICOXIB	n/a	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	TOLMETIN	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	DIHOMO-GAMMA-LINOLENIC ACID	n/a	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	NEPAFENAC	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	FENOPROFEN	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	FLURBIPROFEN	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	ANTIPYRINE	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	PHENYLBUTAZONE	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	OXAPROZIN	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	NIMESULIDE	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	MAGNESIUM SALICYLATE	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	DIFLUNISAL	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	ETODOLAC	inhibitor	DrugBank	drug resistance,druggable genome,tumor suppressor
PTGS2	CELECOXIB	inhibitor	MyCancerGenomeClinicalTrial	drug resistance,druggable genome,tumor suppressor
PLAU	6-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	6-[N-(4-ETHYL-1,2,3,4-TETRAHYDRO-6-ISOQUINOLINYL)CARBAMYL]-2-NAPHTHALENECARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	8-(PYRIMIDIN-2-YLAMINO)NAPHTHALENE-2-CARBOXIMIDAMIDE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	[2,4,6-TRIISOPROPYL-PHENYLSULFONYL-L-[3-AMIDINO-PHENYLALANINE]]-PIPERAZINE-N'-BETA-ALANINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	1-[4-(2-OXO-2-PHENYLETHYL)PHENYL]GUANIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	N-(1-ADAMANTYL)-N'-(4-GUANIDINOBENZYL)UREA	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	AMILORIDE	inhibitor	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	6-CHLORO-2-(2-HYDROXY-BIPHENYL-3-YL)-1H-INDOLE-5-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	TRANS-6-(2-PHENYLCYCLOPROPYL)-NAPHTHALENE-2-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	BENZAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	2-(2-HYDROXY-5-METHOXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	7-METHOXY-8-[1-(METHYLSULFONYL)-1H-PYRAZOL-4-YL]NAPHTHALENE-2-CARBOXIMIDAMIDE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	6-FLUORO-2-(2-HYDROXY-3-ISOBUTOXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	6-[N-(1-ISOPROPYL-1,2,3,4-TETRAHYDRO-7-ISOQUINOLINYL)CARBAMYL]-2-NAPHTHALENECARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	WX-671	n/a	TdgClinicalTrial	cell surface,druggable genome,kinase,protease
PLAU	WX-UK1	n/a	TdgClinicalTrial	cell surface,druggable genome,kinase,protease
PLAU	WX-UK1	n/a	GuideToPharmacologyInteractions	cell surface,druggable genome,kinase,protease
PLAU	UPAMOSTAT	n/a	GuideToPharmacologyInteractions	cell surface,druggable genome,kinase,protease
PLAU	6-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	6-[N-(4-ETHYL-1,2,3,4-TETRAHYDRO-6-ISOQUINOLINYL)CARBAMYL]-2-NAPHTHALENECARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	8-(PYRIMIDIN-2-YLAMINO)NAPHTHALENE-2-CARBOXIMIDAMIDE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	[2,4,6-TRIISOPROPYL-PHENYLSULFONYL-L-[3-AMIDINO-PHENYLALANINE]]-PIPERAZINE-N'-BETA-ALANINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	1-[4-(2-OXO-2-PHENYLETHYL)PHENYL]GUANIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	N-(1-ADAMANTYL)-N'-(4-GUANIDINOBENZYL)UREA	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	AMILORIDE	inhibitor	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	6-CHLORO-2-(2-HYDROXY-BIPHENYL-3-YL)-1H-INDOLE-5-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	TRANS-6-(2-PHENYLCYCLOPROPYL)-NAPHTHALENE-2-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	BENZAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	2-(2-HYDROXY-5-METHOXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	7-METHOXY-8-[1-(METHYLSULFONYL)-1H-PYRAZOL-4-YL]NAPHTHALENE-2-CARBOXIMIDAMIDE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	6-FLUORO-2-(2-HYDROXY-3-ISOBUTOXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	6-[N-(1-ISOPROPYL-1,2,3,4-TETRAHYDRO-7-ISOQUINOLINYL)CARBAMYL]-2-NAPHTHALENECARBOXAMIDINE	n/a	DrugBank	cell surface,druggable genome,kinase,protease
PLAU	WX-671	n/a	TdgClinicalTrial	cell surface,druggable genome,kinase,protease
PLAU	WX-UK1	n/a	TdgClinicalTrial	cell surface,druggable genome,kinase,protease
PLAU	WX-UK1	n/a	GuideToPharmacologyInteractions	cell surface,druggable genome,kinase,protease
PLAU	UPAMOSTAT	n/a	GuideToPharmacologyInteractions	cell surface,druggable genome,kinase,protease
SERPINE1	TROGLITAZONE	antagonist	DrugBank	druggable genome,protease inhibitor
CD47	ABT-510	n/a	TdgClinicalTrial	
ANXA5	1,4-DIDEOXY-5-DEHYDRO-O2-SULFO-GLUCURONIC ACID	n/a	DrugBank	cell surface,external side of plasma membrane
ANXA5	1,4-DIDEOXY-O2-SULFO-GLUCURONIC ACID	n/a	DrugBank	cell surface,external side of plasma membrane
ANXA5	L-ALPHA-GLYCEROPHOSPHORYLSERINE	n/a	DrugBank	cell surface,external side of plasma membrane
WARS	L-TRYPTOPHAN	inhibitor	DrugBank	druggable genome
WARS	TRYPTOPHANYL-5'AMP	n/a	DrugBank	druggable genome
WARS	L-TRYPTOPHANAMIDE	n/a	DrugBank	druggable genome
PDE4B	4-[8-(3-NITROPHENYL)-1,7-NAPHTHYRIDIN-6-YL]BENZOIC ACID	n/a	DrugBank	drug resistance,druggable genome
PDE4B	S,S-(2-HYDROXYETHYL)THIOCYSTEINE	n/a	DrugBank	drug resistance,druggable genome
PDE4B	DYPHYLLINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	1-(2-CHLOROPHENYL)-3,5-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER	n/a	DrugBank	drug resistance,druggable genome
PDE4B	KETOTIFEN	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	ILOPROST	inducer	DrugBank	drug resistance,druggable genome
PDE4B	THEOPHYLLINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	8-BROMO-ADENOSINE-5'-MONOPHOSPHATE	n/a	DrugBank	drug resistance,druggable genome
PDE4B	CAFFEINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	PAPAVERINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	ENPROFYLLINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	PENTOXIFYLLINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	PICLAMILAST	n/a	DrugBank	drug resistance,druggable genome
PDE4B	THEOBROMINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	ROFLUMILAST	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	IBUDILAST	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	AMRINONE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	FILAMINAST	n/a	DrugBank	drug resistance,druggable genome
PDE4B	APREMILAST	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	THEOPHYLLINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	ENPROFYLLINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	CAFFEINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	RESVERATROL	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	DYPHYLLINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	IBUDILAST	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	OGLEMILAST	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	RESVERATROL	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	ROFLUMILAST	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	PENTOXIFYLLINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	ETAZOLATE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	AMRINONE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	PAPAVERINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	AMRINONE	n/a	TEND	drug resistance,druggable genome
PDE4B	DYPHYLLINE	n/a	TEND	drug resistance,druggable genome
PDE4B	ENPROFYLLINE	n/a	TEND	drug resistance,druggable genome
PDE4B	THEOPHYLLINE	n/a	TEND	drug resistance,druggable genome
PDE4B	PENTOXIFYLLINE	n/a	TEND	drug resistance,druggable genome
PDE4B	PAPAVERINE	n/a	TEND	drug resistance,druggable genome
PDE4B	CAFFEINE	n/a	TEND	drug resistance,druggable genome
PDE4B	ROFLUMILAST	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
PDE4B	IBUDILAST	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
PDE4B	ROLIPRAM	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
PDE4B	RS-25344	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
PDE4B	4-[8-(3-NITROPHENYL)-1,7-NAPHTHYRIDIN-6-YL]BENZOIC ACID	n/a	DrugBank	drug resistance,druggable genome
PDE4B	S,S-(2-HYDROXYETHYL)THIOCYSTEINE	n/a	DrugBank	drug resistance,druggable genome
PDE4B	DYPHYLLINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	1-(2-CHLOROPHENYL)-3,5-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER	n/a	DrugBank	drug resistance,druggable genome
PDE4B	KETOTIFEN	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	ILOPROST	inducer	DrugBank	drug resistance,druggable genome
PDE4B	THEOPHYLLINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	8-BROMO-ADENOSINE-5'-MONOPHOSPHATE	n/a	DrugBank	drug resistance,druggable genome
PDE4B	CAFFEINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	PAPAVERINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	ENPROFYLLINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	PENTOXIFYLLINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	PICLAMILAST	n/a	DrugBank	drug resistance,druggable genome
PDE4B	THEOBROMINE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	ROFLUMILAST	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	IBUDILAST	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	AMRINONE	inhibitor	DrugBank	drug resistance,druggable genome
PDE4B	FILAMINAST	n/a	DrugBank	drug resistance,druggable genome
PDE4B	APREMILAST	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	THEOPHYLLINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	ENPROFYLLINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	CAFFEINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	RESVERATROL	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	DYPHYLLINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	IBUDILAST	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	OGLEMILAST	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	RESVERATROL	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	ROFLUMILAST	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	PENTOXIFYLLINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	ETAZOLATE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	AMRINONE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	PAPAVERINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
PDE4B	AMRINONE	n/a	TEND	drug resistance,druggable genome
PDE4B	DYPHYLLINE	n/a	TEND	drug resistance,druggable genome
PDE4B	ENPROFYLLINE	n/a	TEND	drug resistance,druggable genome
PDE4B	THEOPHYLLINE	n/a	TEND	drug resistance,druggable genome
PDE4B	PENTOXIFYLLINE	n/a	TEND	drug resistance,druggable genome
PDE4B	PAPAVERINE	n/a	TEND	drug resistance,druggable genome
PDE4B	CAFFEINE	n/a	TEND	drug resistance,druggable genome
PDE4B	ROFLUMILAST	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
PDE4B	IBUDILAST	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
PDE4B	ROLIPRAM	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
PDE4B	RS-25344	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
MMP1	BMS 275291	inhibitor	TTD	druggable genome,neutral zinc metallopeptidase,protease
MMP1	MARIMASTAT	inhibitor	TTD	druggable genome,neutral zinc metallopeptidase,protease
MMP1	BATIMASTAT	inhibitor	TTD	druggable genome,neutral zinc metallopeptidase,protease
MMP1	PRINOMASTAT	inhibitor	TTD	druggable genome,neutral zinc metallopeptidase,protease
MMP1	DOXYCYCLINE HYDRATE	inhibitor	ChEMBL	druggable genome,neutral zinc metallopeptidase,protease
MMP1	DOXYCYCLINE CALCIUM	inhibitor	ChEMBL	druggable genome,neutral zinc metallopeptidase,protease
MMP1	DOXYCYCLINE HYCLATE	inhibitor	ChEMBL	druggable genome,neutral zinc metallopeptidase,protease
MMP1	MARIMASTAT	inhibitor	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP1	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP1	N-HYDROXY-2-[4-(4-PHENOXY-BENZENESULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP1	CIPEMASTAT	n/a	GuideToPharmacologyInteractions	druggable genome,neutral zinc metallopeptidase,protease
MMP1	BMS 275291	inhibitor	TTD	druggable genome,neutral zinc metallopeptidase,protease
MMP1	MARIMASTAT	inhibitor	TTD	druggable genome,neutral zinc metallopeptidase,protease
MMP1	BATIMASTAT	inhibitor	TTD	druggable genome,neutral zinc metallopeptidase,protease
MMP1	PRINOMASTAT	inhibitor	TTD	druggable genome,neutral zinc metallopeptidase,protease
MMP1	DOXYCYCLINE HYDRATE	inhibitor	ChEMBL	druggable genome,neutral zinc metallopeptidase,protease
MMP1	DOXYCYCLINE CALCIUM	inhibitor	ChEMBL	druggable genome,neutral zinc metallopeptidase,protease
MMP1	DOXYCYCLINE HYCLATE	inhibitor	ChEMBL	druggable genome,neutral zinc metallopeptidase,protease
MMP1	MARIMASTAT	inhibitor	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP1	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP1	N-HYDROXY-2-[4-(4-PHENOXY-BENZENESULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP1	CIPEMASTAT	n/a	GuideToPharmacologyInteractions	druggable genome,neutral zinc metallopeptidase,protease
IL1B	MINOCYCLINE	modulator	DrugBank	drug resistance,tumor suppressor
IL1B	VX-765	n/a	DrugBank	drug resistance,tumor suppressor
IL1B	GALLIUM NITRATE	antagonist	DrugBank	drug resistance,tumor suppressor
IL1B	VX-702	n/a	DrugBank	drug resistance,tumor suppressor
IL1B	CLODRONATE	n/a	PharmGKB	drug resistance,tumor suppressor
IL1B	GALLIUM NITRATE	inhibitor	TTD	drug resistance,tumor suppressor
IL1B	IBUDILAST	inhibitor	TTD	drug resistance,tumor suppressor
AKR1B10	TOLRESTAT	n/a	DrugBank	druggable genome
AKR1B10	2'-MONOPHOSPHOADENOSINE 5'-DIPHOSPHORIBOSE	n/a	DrugBank	druggable genome
IDO1	L-TRYPTOPHAN	binder	TTD	
SLC2A3	GLUFOSFAMIDE	n/a	TdgClinicalTrial	druggable genome,transporter
SLC2A3	GLUFOSFAMIDE	n/a	TdgClinicalTrial	druggable genome,transporter
STS	2-AMINO-3-OXO-4-SULFO-BUTYRIC ACID	n/a	DrugBank	druggable genome
ANXA1	HYDROCORTAMATE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	PREDNICARBATE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	TRIAMCINOLONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	PREDNISONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	DESOXIMETASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	RIMEXOLONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	CLOCORTOLONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	FLUMETHASONE PIVALATE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	AMCINONIDE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	METHYLPREDNISOLONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	BECLOMETHASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	DESONIDE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	DEXAMETHASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	BETAMETHASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	CLOBETASOL	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	MOMETASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	LOTEPREDNOL ETABONATE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	ALCLOMETASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	DIFLORASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	PREDNISOLONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	HALOBETASOL PROPIONATE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	HYDROCORTISONE	agonist	DrugBank	cell surface,drug resistance,tumor suppressor
ANXA1	DEXAMETHASONE	agonist	DrugBank	cell surface,drug resistance,tumor suppressor
ANXA1	AMCINONIDE	agonist	DrugBank	cell surface,drug resistance,tumor suppressor
ANXA1	HYDROCORTAMATE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	PREDNICARBATE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	TRIAMCINOLONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	PREDNISONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	DESOXIMETASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	RIMEXOLONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	CLOCORTOLONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	FLUMETHASONE PIVALATE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	AMCINONIDE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	METHYLPREDNISOLONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	BECLOMETHASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	DESONIDE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	DEXAMETHASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	BETAMETHASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	CLOBETASOL	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	MOMETASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	LOTEPREDNOL ETABONATE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	ALCLOMETASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	DIFLORASONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	PREDNISOLONE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	HALOBETASOL PROPIONATE	n/a	TEND	cell surface,drug resistance,tumor suppressor
ANXA1	HYDROCORTISONE	agonist	DrugBank	cell surface,drug resistance,tumor suppressor
ANXA1	DEXAMETHASONE	agonist	DrugBank	cell surface,drug resistance,tumor suppressor
ANXA1	AMCINONIDE	agonist	DrugBank	cell surface,drug resistance,tumor suppressor
LYN	BOSUTINIB	n/a	DrugBank	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	NINTEDANIB	inhibitor	DrugBank	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	PONATINIB	inhibitor	DrugBank	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	MASITINIB	n/a	TdgClinicalTrial	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	SU6656	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	BOSUTINIB	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	MASITINIB	inhibitor	MyCancerGenomeClinicalTrial	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	BOSUTINIB	inhibitor	ChEMBL	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	BOSUTINIB	n/a	DrugBank	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	NINTEDANIB	inhibitor	DrugBank	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	PONATINIB	inhibitor	DrugBank	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	MASITINIB	n/a	TdgClinicalTrial	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	SU6656	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	BOSUTINIB	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	MASITINIB	inhibitor	MyCancerGenomeClinicalTrial	drug resistance,druggable genome,kinase,tyrosine kinase
LYN	BOSUTINIB	inhibitor	ChEMBL	drug resistance,druggable genome,kinase,tyrosine kinase
MTHFD2	TETRAHYDROFOLIC ACID	cofactor	DrugBank	
ADM	PAROXETINE	n/a	PharmGKB	hormone activity
ACOX1	(3R)-3-HYDROXYDODECANOIC ACID	n/a	DrugBank	
TIMP1	PACLITAXEL	n/a	CIViC	druggable genome,growth factor,protease inhibitor
NAMPT	N-[4-(1-BENZOYLPIPERIDIN-4-YL)BUTYL]-3-PYRIDIN-3-YLPROPANAMIDE	n/a	DrugBank	
PLA2G7	DARAPLADIB	n/a	GuideToPharmacologyInteractions	lipase,phospholipase
PLA2G7	RILAPLADIB	n/a	GuideToPharmacologyInteractions	lipase,phospholipase
PLA2G7	DARAPLADIB	inhibitor	TTD	lipase,phospholipase
PLA2G7	RILAPLADIB	inhibitor	TTD	lipase,phospholipase
PLA2G7	(1R)-1,2,2-TRIMETHYLPROPYL (R)-METHYLPHOSPHINATE	n/a	DrugBank	lipase,phospholipase
PLA2G7	DARAPLADIB	n/a	TdgClinicalTrial	lipase,phospholipase
IRS1	[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID	n/a	DrugBank	clinically actionable
HCAR3	MEPENZOLATE	n/a	TEND	druggable genome,g protein coupled receptor
HCAR3	MEPENZOLATE	n/a	TdgClinicalTrial	druggable genome,g protein coupled receptor
HCAR3	ACIFRAN	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
HCAR3	2-HYDROXYOCTANOIC ACID	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
HCAR3	NICOTINIC ACID	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
HCAR3	D-TRYPTOPHAN	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
HCAR3	3-HYDROXYOCTANOIC ACID	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
HCAR3	D-PHENYLALANINE	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
HCAR3	D-KYNURENINE	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
ACSL4	ROSIGLITAZONE	inhibitor	DrugBank	
ACSL4	TROGLITAZONE	inhibitor	DrugBank	
HCK	QUERCETIN	n/a	DrugBank	druggable genome,kinase,tyrosine kinase
HCK	BOSUTINIB	inhibitor	DrugBank	druggable genome,kinase,tyrosine kinase
HCK	BOSUTINIB	inhibitor	ChEMBL	druggable genome,kinase,tyrosine kinase
HCK	MASITINIB	n/a	TdgClinicalTrial	druggable genome,kinase,tyrosine kinase
HCK	QUERCETIN	n/a	DrugBank	druggable genome,kinase,tyrosine kinase
HCK	BOSUTINIB	inhibitor	DrugBank	druggable genome,kinase,tyrosine kinase
HCK	BOSUTINIB	inhibitor	ChEMBL	druggable genome,kinase,tyrosine kinase
HCK	MASITINIB	n/a	TdgClinicalTrial	druggable genome,kinase,tyrosine kinase
CXCR2	SB 225002	n/a	GuideToPharmacologyInteractions	cell surface,druggable genome,g protein coupled receptor
CXCR2	SB-656933	antagonist	TTD	cell surface,druggable genome,g protein coupled receptor
CXCR2	SB-656933	antagonist	TTD	cell surface,druggable genome,g protein coupled receptor
CXCR2	SCH-527123	antagonist	TTD	cell surface,druggable genome,g protein coupled receptor
CXCR2	SCH-527123	n/a	TdgClinicalTrial	cell surface,druggable genome,g protein coupled receptor
CXCR2	SB 225002	n/a	GuideToPharmacologyInteractions	cell surface,druggable genome,g protein coupled receptor
CXCR2	SB-656933	antagonist	TTD	cell surface,druggable genome,g protein coupled receptor
CXCR2	SB-656933	antagonist	TTD	cell surface,druggable genome,g protein coupled receptor
CXCR2	SCH-527123	antagonist	TTD	cell surface,druggable genome,g protein coupled receptor
CXCR2	SCH-527123	n/a	TdgClinicalTrial	cell surface,druggable genome,g protein coupled receptor
GCH1	GUANINE	inhibitor	DrugBank	
MMP3	MARIMASTAT	n/a	TdgClinicalTrial	druggable genome,neutral zinc metallopeptidase,protease
MMP3	N-HYDROXY 1N(4-METHOXYPHENYL)SULFONYL-4-(Z,E-N-METHOXYIMINO)PYRROLIDINE-2R-CARBOXAMIDE	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	[4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	3-(1H-INDOL-3-YL)-2-[4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-PROPIONIC ACID	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	R-2-{[4'-METHOXY-(1,1'-BIPHENYL)-4-YL]-SULFONYL}-AMINO-6-METHOXY-HEX-4-YNOIC ACID	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	HYDROXYAMINOVALINE	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	A DISUBSTITUTED SUCCINYL CAPROLACTAM HYDROXYMATE MMP3INHIBITOR	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	3-METHYLPYRIDINE	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	[2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	1-METHYLOXY-4-SULFONE-BENZENE	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	MARIMASTAT	antagonist	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	PG-116800	inhibitor	TTD	druggable genome,neutral zinc metallopeptidase,protease
MMP3	UK-356618	n/a	GuideToPharmacologyInteractions	druggable genome,neutral zinc metallopeptidase,protease
MMP3	MARIMASTAT	n/a	TEND	druggable genome,neutral zinc metallopeptidase,protease
MMP3	MARIMASTAT	n/a	TdgClinicalTrial	druggable genome,neutral zinc metallopeptidase,protease
MMP3	N-HYDROXY 1N(4-METHOXYPHENYL)SULFONYL-4-(Z,E-N-METHOXYIMINO)PYRROLIDINE-2R-CARBOXAMIDE	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	[4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	3-(1H-INDOL-3-YL)-2-[4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-PROPIONIC ACID	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	R-2-{[4'-METHOXY-(1,1'-BIPHENYL)-4-YL]-SULFONYL}-AMINO-6-METHOXY-HEX-4-YNOIC ACID	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	HYDROXYAMINOVALINE	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	A DISUBSTITUTED SUCCINYL CAPROLACTAM HYDROXYMATE MMP3INHIBITOR	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	3-METHYLPYRIDINE	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	[2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	1-METHYLOXY-4-SULFONE-BENZENE	n/a	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	MARIMASTAT	antagonist	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP3	PG-116800	inhibitor	TTD	druggable genome,neutral zinc metallopeptidase,protease
MMP3	UK-356618	n/a	GuideToPharmacologyInteractions	druggable genome,neutral zinc metallopeptidase,protease
MMP3	MARIMASTAT	n/a	TEND	druggable genome,neutral zinc metallopeptidase,protease
CD55	CHLORAMPHENICOL	other/unknown	DrugBank	cell surface
CCL2	RS-504393	inhibitor	TTD	drug resistance,kinase
CCL2	MIMOSINE	inhibitor	DrugBank	drug resistance,kinase
CCL2	DANAZOL	inhibitor	DrugBank	drug resistance,kinase
ICAM1	ALICAFORSEN	n/a	TdgClinicalTrial	cell surface,drug resistance,external side of plasma membrane
ICAM1	ALICAFORSEN	antisense	TTD	cell surface,drug resistance,external side of plasma membrane
ALCAM	5-FLUOROURIDINE	n/a	CIViC	cell surface,external side of plasma membrane
HK2	4-AMINOPYRIDINE	blocker	TTD	kinase
HK2	AZIMILIDE	blocker	TTD	kinase
HK2	DRONEDARONE	blocker	TTD	kinase
LDLR	PORFIMER	other/unknown	DrugBank	cell surface,external side of plasma membrane
LDLR	ATENOLOL	n/a	PharmGKB	cell surface,external side of plasma membrane
ATP2C1	SEVOFLURANE	inhibitor	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	ENFLURANE	inhibitor	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	ISOFLURANE	inhibitor	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	HALOTHANE	other/unknown	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	METHOXYFLURANE	inhibitor	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	DESFLURANE	inhibitor	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	CALCIUM	agonist	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	SEVOFLURANE	n/a	TEND	abc transporter,druggable genome,transporter
ATP2C1	ENFLURANE	n/a	TEND	abc transporter,druggable genome,transporter
ATP2C1	DESFLURANE	n/a	TEND	abc transporter,druggable genome,transporter
ATP2C1	ISOFLURANE	n/a	TEND	abc transporter,druggable genome,transporter
ATP2C1	ISOFLURANE	n/a	TdgClinicalTrial	abc transporter,druggable genome,transporter
ATP2C1	SEVOFLURANE	n/a	TdgClinicalTrial	abc transporter,druggable genome,transporter
ATP2C1	DESFLURANE	n/a	TdgClinicalTrial	abc transporter,druggable genome,transporter
ATP2C1	ENFLURANE	n/a	TdgClinicalTrial	abc transporter,druggable genome,transporter
ATP2C1	SEVOFLURANE	inhibitor	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	ENFLURANE	inhibitor	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	ISOFLURANE	inhibitor	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	HALOTHANE	other/unknown	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	METHOXYFLURANE	inhibitor	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	DESFLURANE	inhibitor	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	CALCIUM	agonist	DrugBank	abc transporter,druggable genome,transporter
ATP2C1	SEVOFLURANE	n/a	TEND	abc transporter,druggable genome,transporter
ATP2C1	ENFLURANE	n/a	TEND	abc transporter,druggable genome,transporter
ATP2C1	DESFLURANE	n/a	TEND	abc transporter,druggable genome,transporter
ATP2C1	ISOFLURANE	n/a	TEND	abc transporter,druggable genome,transporter
ATP2C1	ISOFLURANE	n/a	TdgClinicalTrial	abc transporter,druggable genome,transporter
ATP2C1	SEVOFLURANE	n/a	TdgClinicalTrial	abc transporter,druggable genome,transporter
ATP2C1	DESFLURANE	n/a	TdgClinicalTrial	abc transporter,druggable genome,transporter
ATP2C1	ENFLURANE	n/a	TdgClinicalTrial	abc transporter,druggable genome,transporter
CFB	4-GUANIDINOBENZOIC ACID	n/a	DrugBank	druggable genome,protease
CFB	4-GUANIDINOBENZOIC ACID	n/a	DrugBank	druggable genome,protease
NOS2	AMINOGUANIDINE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
NOS2	2-AMINO-4-METHYLPYRIDINE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
NOS2	TRIFLUSAL	agonist	DrugBank	drug resistance,druggable genome
NOS2	S-ETHYLISOTHIOUREA	n/a	DrugBank	drug resistance,druggable genome
NOS2	7,8-DIHYDRO-L-BIOPTERIN	n/a	DrugBank	drug resistance,druggable genome
NOS2	1-[4-(AMINOMETHYL)BENZOYL]-5'-FLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLIN]-4'-AMINE	n/a	DrugBank	drug resistance,druggable genome
NOS2	L-CITRULLINE	n/a	DrugBank	drug resistance,druggable genome
NOS2	(3R)-3-[(1,2,3,4-TETRAHYDROISOQUINOLIN-7-YLOXY)METHYL]-2,3-DIHYDROTHIENO[2,3-F][1,4]OXAZEPIN-5-AMINE	n/a	DrugBank	drug resistance,druggable genome
NOS2	DEXAMETHASONE	negative modulator	DrugBank	drug resistance,druggable genome
NOS2	7,8-DIHYDROBIOPTERIN	n/a	DrugBank	drug resistance,druggable genome
NOS2	N,N-DIMETHYLARGININE	n/a	DrugBank	drug resistance,druggable genome
NOS2	4R-FLUORO-N6-ETHANIMIDOYL-L-LYSINE	n/a	DrugBank	drug resistance,druggable genome
NOS2	ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE	n/a	DrugBank	drug resistance,druggable genome
NOS2	THIOCOUMARIN	n/a	DrugBank	drug resistance,druggable genome
NOS2	N-(3-(AMINOMETHYL)BENZYL)ACETAMIDINE	n/a	DrugBank	drug resistance,druggable genome
NOS2	L-ARGININE	n/a	DrugBank	drug resistance,druggable genome
NOS2	ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE	n/a	DrugBank	drug resistance,druggable genome
NOS2	7-NITROINDAZOLE	n/a	DrugBank	drug resistance,druggable genome
NOS2	L-THIOCITRULLINE	n/a	DrugBank	drug resistance,druggable genome
NOS2	MICONAZOLE	inhibitor	DrugBank	drug resistance,druggable genome
NOS2	5-(4'-AMINO-1'-ETHYL-5',8'-DIFLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLINE]-1-YLCARBONYL)PICOLINONITRILE	n/a	DrugBank	drug resistance,druggable genome
NOS2	AMINOGUANIDINE	inhibitor	DrugBank	drug resistance,druggable genome
NOS2	N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDE	n/a	DrugBank	drug resistance,druggable genome
NOS2	N-[2-(4-AMINO-5,8-DIFLUORO-1,2-DIHYDROQUINAZOLIN-2-YL)ETHYL]-3-FURAMIDE	n/a	DrugBank	drug resistance,druggable genome
NOS2	5-NITROINDAZOLE	n/a	DrugBank	drug resistance,druggable genome
NOS2	(2S)-2-METHYL-2,3-DIHYDROTHIENO[2,3-F][1,4]OXAZEPIN-5-AMINE	n/a	DrugBank	drug resistance,druggable genome
NOS2	N-OMEGA-HYDROXY-L-ARGININE	n/a	DrugBank	drug resistance,druggable genome
NOS2	N-OMEGA-PROPYL-L-ARGININE	n/a	DrugBank	drug resistance,druggable genome
NOS2	DOXYCYCLINE	inhibitor	MyCancerGenomeClinicalTrial	drug resistance,druggable genome
PRKAR1A	SP-ADENOSINE-3',5'-CYCLIC-MONOPHOSPHOROTHIOATE	n/a	DrugBank	clinically actionable,kinase,serine threonine kinase,tumor suppressor
PRKAR1A	CYCLIC ADENOSINE MONOPHOSPHATE	n/a	DrugBank	clinically actionable,kinase,serine threonine kinase,tumor suppressor
PRKAR1A	SP-ADENOSINE-3',5'-CYCLIC-MONOPHOSPHOROTHIOATE	n/a	DrugBank	clinically actionable,kinase,serine threonine kinase,tumor suppressor
PRKAR1A	CYCLIC ADENOSINE MONOPHOSPHATE	n/a	DrugBank	clinically actionable,kinase,serine threonine kinase,tumor suppressor
CTSK	BALICATIB	n/a	GuideToPharmacologyInteractions	druggable genome,protease
CTSK	RELACATIB	n/a	GuideToPharmacologyInteractions	druggable genome,protease
CTSK	ODANACATIB	n/a	GuideToPharmacologyInteractions	druggable genome,protease
CTSK	N2-({[(4-BROMOPHENYL)METHYL]OXY}CARBONYL)-N1-[(1S)-1-FORMYLPENTYL]-L-LEUCINAMIDE	n/a	DrugBank	druggable genome,protease
CTSK	N-(2-AMINOETHYL)-N~2~-{(1S)-1-[4'-(AMINOSULFONYL)BIPHENYL-4-YL]-2,2,2-TRIFLUOROETHYL}-L-LEUCINAMIDE	n/a	DrugBank	druggable genome,protease
CTSK	1,5-BIS(N-BENZYLOXYCARBONYL-L-LEUCINYL)CARBOHYDRAZIDE	n/a	DrugBank	druggable genome,protease
CTSK	TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE	n/a	DrugBank	druggable genome,protease
CTSK	1-[N[(PHENYLMETHOXY)CARBONYL]-L-LEUCYL-4-[[N/N-[(PHENYLMETHOXY)CARBONYL]-/NL-LEUCYL]AMINO]-3-PYRROLIDINONE/N	n/a	DrugBank	druggable genome,protease
CTSK	3-AMINO-5-PHENYLPENTANE	n/a	DrugBank	druggable genome,protease
CTSK	BENZOFURAN-2-CARBOXYLIC ACID {(S)-3-METHYL-1-[3-OXO-1-(PYRIDIN-2-YLSULFONYL)AZEPAN-4-YLCARBAMOYL]BUTYL}AMIDE	n/a	DrugBank	druggable genome,protease
CTSK	(1R,2R)-N-(2-AMINOETHYL)-2-{[(4-METHOXYPHENYL)SULFONYL]METHYL}CYCLOHEXANECARBOXAMIDE	n/a	DrugBank	druggable genome,protease
CTSK	1-[2-(3-BIPHENYL)-4-METHYLVALERYL)]AMINO-3-(2-PYRIDYLSULFONYL)AMINO-2-PROPANONE	n/a	DrugBank	druggable genome,protease
CTSK	1-{7-CYCLOHEXYL-6-[4-(4-METHYLPIPERAZIN-1-YL)BENZYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-2-YL}METHANAMINE	n/a	DrugBank	druggable genome,protease
CTSK	N2-[(BENZYLOXY)CARBONYL]-N1-[(3S)-1-CYANOPYRROLIDIN-3-YL]-L-LEUCINAMIDE	n/a	DrugBank	druggable genome,protease
CTSK	RELACATIB	n/a	TdgClinicalTrial	druggable genome,protease
CTSK	ODANACATIB	n/a	TdgClinicalTrial	druggable genome,protease
CTSK	ODANACATIB	inhibitor	TALC	druggable genome,protease
CTSK	BALICATIB	inhibitor	TALC	druggable genome,protease
CTSK	BALICATIB	n/a	GuideToPharmacologyInteractions	druggable genome,protease
CTSK	RELACATIB	n/a	GuideToPharmacologyInteractions	druggable genome,protease
CTSK	ODANACATIB	n/a	GuideToPharmacologyInteractions	druggable genome,protease
CTSK	N2-({[(4-BROMOPHENYL)METHYL]OXY}CARBONYL)-N1-[(1S)-1-FORMYLPENTYL]-L-LEUCINAMIDE	n/a	DrugBank	druggable genome,protease
CTSK	N-(2-AMINOETHYL)-N~2~-{(1S)-1-[4'-(AMINOSULFONYL)BIPHENYL-4-YL]-2,2,2-TRIFLUOROETHYL}-L-LEUCINAMIDE	n/a	DrugBank	druggable genome,protease
CTSK	1,5-BIS(N-BENZYLOXYCARBONYL-L-LEUCINYL)CARBOHYDRAZIDE	n/a	DrugBank	druggable genome,protease
CTSK	TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE	n/a	DrugBank	druggable genome,protease
CTSK	1-[N[(PHENYLMETHOXY)CARBONYL]-L-LEUCYL-4-[[N/N-[(PHENYLMETHOXY)CARBONYL]-/NL-LEUCYL]AMINO]-3-PYRROLIDINONE/N	n/a	DrugBank	druggable genome,protease
CTSK	3-AMINO-5-PHENYLPENTANE	n/a	DrugBank	druggable genome,protease
CTSK	BENZOFURAN-2-CARBOXYLIC ACID {(S)-3-METHYL-1-[3-OXO-1-(PYRIDIN-2-YLSULFONYL)AZEPAN-4-YLCARBAMOYL]BUTYL}AMIDE	n/a	DrugBank	druggable genome,protease
CTSK	(1R,2R)-N-(2-AMINOETHYL)-2-{[(4-METHOXYPHENYL)SULFONYL]METHYL}CYCLOHEXANECARBOXAMIDE	n/a	DrugBank	druggable genome,protease
CTSK	1-[2-(3-BIPHENYL)-4-METHYLVALERYL)]AMINO-3-(2-PYRIDYLSULFONYL)AMINO-2-PROPANONE	n/a	DrugBank	druggable genome,protease
CTSK	1-{7-CYCLOHEXYL-6-[4-(4-METHYLPIPERAZIN-1-YL)BENZYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-2-YL}METHANAMINE	n/a	DrugBank	druggable genome,protease
CTSK	N2-[(BENZYLOXY)CARBONYL]-N1-[(3S)-1-CYANOPYRROLIDIN-3-YL]-L-LEUCINAMIDE	n/a	DrugBank	druggable genome,protease
CTSK	RELACATIB	n/a	TdgClinicalTrial	druggable genome,protease
CTSK	ODANACATIB	n/a	TdgClinicalTrial	druggable genome,protease
CTSK	ODANACATIB	inhibitor	TALC	druggable genome,protease
CTSK	BALICATIB	inhibitor	TALC	druggable genome,protease
ADH1C	(R)-N-(1-METHYL-HEXYL)-FORMAMIDE	n/a	DrugBank	druggable genome
ADH1C	5-BETA-D-RIBOFURANOSYLNICOTINAMIDE ADENINE DINUCLEOTIDE	n/a	DrugBank	druggable genome
ADH1C	N-1-METHYLHEPTYLFORMAMIDE	n/a	DrugBank	druggable genome
ADH1C	2,3,4,5,6-PENTAFLUOROBENZYL ALCOHOL	n/a	DrugBank	druggable genome
ADH1C	N-FORMYLPIPERIDINE	n/a	DrugBank	druggable genome
ADH1C	CHOLIC ACID	n/a	DrugBank	druggable genome
ADH1C	4-IODOPYRAZOLE	n/a	DrugBank	druggable genome
ADH1C	2-ETHOXYETHANOL	n/a	DrugBank	druggable genome
ADH1C	3-BUTYLTHIOLANE 1-OXIDE	n/a	DrugBank	druggable genome
ADH1C	PYRAZOLE	n/a	DrugBank	druggable genome
ADH1C	CPAD	n/a	DrugBank	druggable genome
ADH1C	2,3-DIFLUOROBENZYL ALCOHOL	n/a	DrugBank	druggable genome
ADH1C	ETHANOL	n/a	PharmGKB	druggable genome
SERPINB5	S,S-(2-HYDROXYETHYL)THIOCYSTEINE	n/a	DrugBank	druggable genome,protease inhibitor
SERPINB5	S,S-(2-HYDROXYETHYL)THIOCYSTEINE	n/a	DrugBank	druggable genome,protease inhibitor
TLR2	S-(DIMETHYLARSENIC)CYSTEINE	n/a	DrugBank	cell surface,drug resistance,external side of plasma membrane
TLR2	PEPTIDOGLYCAN	n/a	GuideToPharmacologyInteractions	cell surface,drug resistance,external side of plasma membrane
TLR2	DIAPEP277	n/a	TdgClinicalTrial	cell surface,drug resistance,external side of plasma membrane
HIF1A	N-[(1-CHLORO-4-HYDROXYISOQUINOLIN-3-YL)CARBONYL]GLYCINE	n/a	DrugBank	transcription factor binding,transcription factor complex
HIF1A	2-METHOXYESTRADIOL	n/a	DrugBank	transcription factor binding,transcription factor complex
HIF1A	CARVEDILOL	modulator	DrugBank	transcription factor binding,transcription factor complex
HIF1A	PX-478	inhibitor	TALC	transcription factor binding,transcription factor complex
HIF1A	NOSCAPINE	n/a	TdgClinicalTrial	transcription factor binding,transcription factor complex
HIF1A	ENMD-1198	n/a	TdgClinicalTrial	transcription factor binding,transcription factor complex
HIF1A	PX-478	n/a	TdgClinicalTrial	transcription factor binding,transcription factor complex
HIF1A	NITROGLYCERIN	inhibitor	MyCancerGenomeClinicalTrial	transcription factor binding,transcription factor complex
MMP10	MARIMASTAT	antagonist	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
MMP10	MARIMASTAT	antagonist	DrugBank	druggable genome,neutral zinc metallopeptidase,protease
SLC12A2	PIRETANIDE	n/a	GuideToPharmacologyInteractions	druggable genome,transporter
SLC12A2	FUROSEMIDE	n/a	GuideToPharmacologyInteractions	druggable genome,transporter
SLC12A2	BUMETANIDE	n/a	GuideToPharmacologyInteractions	druggable genome,transporter
SLC12A2	BUMETANIDE	n/a	TdgClinicalTrial	druggable genome,transporter
SLC12A2	QUINETHAZONE	inhibitor	DrugBank	druggable genome,transporter
SLC12A2	BUMETANIDE	inhibitor	DrugBank	druggable genome,transporter
SLC12A2	POTASSIUM CHLORIDE	n/a	DrugBank	druggable genome,transporter
SLC12A2	BUMETANIDE	n/a	TEND	druggable genome,transporter
SLC12A2	ALDOSTERONE	blocker	TTD	druggable genome,transporter
SLC12A2	PIRETANIDE	n/a	GuideToPharmacologyInteractions	druggable genome,transporter
SLC12A2	FUROSEMIDE	n/a	GuideToPharmacologyInteractions	druggable genome,transporter
SLC12A2	BUMETANIDE	n/a	GuideToPharmacologyInteractions	druggable genome,transporter
SLC12A2	BUMETANIDE	n/a	TdgClinicalTrial	druggable genome,transporter
SLC12A2	QUINETHAZONE	inhibitor	DrugBank	druggable genome,transporter
SLC12A2	BUMETANIDE	inhibitor	DrugBank	druggable genome,transporter
SLC12A2	POTASSIUM CHLORIDE	n/a	DrugBank	druggable genome,transporter
SLC12A2	BUMETANIDE	n/a	TEND	druggable genome,transporter
SLC12A2	ALDOSTERONE	blocker	TTD	druggable genome,transporter
MAP3K8	MEK INHIBITOR II	n/a	GuideToPharmacologyInteractions	druggable genome,kinase,serine threonine kinase,tumor suppressor
MAP3K8	TPL2 KINASE INHIBITOR	n/a	GuideToPharmacologyInteractions	druggable genome,kinase,serine threonine kinase,tumor suppressor
MAP3K8	MEK INHIBITOR II	n/a	GuideToPharmacologyInteractions	druggable genome,kinase,serine threonine kinase,tumor suppressor
MAP3K8	TPL2 KINASE INHIBITOR	n/a	GuideToPharmacologyInteractions	druggable genome,kinase,serine threonine kinase,tumor suppressor
PPARG	(5R,6E,8Z,11Z,14Z,17Z)-5-HYDROXYICOSA-6,8,11,14,17-PENTAENOIC ACID	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	SULFASALAZINE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	INDOMETHACIN	activator	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ALEGLITAZAR	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	REPAGLINIDE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	(2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	BALSALAZIDE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	DIFLUORO(5-{2-[(5-OCTYL-1H-PYRROL-2-YL-KAPPAN)METHYLIDENE]-2H-PYRROL-5-YL-KAPPAN}PENTANOATO)BORON	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	NATEGLINIDE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	IBUPROFEN	activator	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	(4S,5E,7Z,10Z,13Z,16Z,19Z)-4-HYDROXYDOCOSA-5,7,10,13,16,19-HEXAENOIC ACID	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	GLIPIZIDE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TELMISARTAN	partial agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	T131	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	BEZAFIBRATE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	(2S)-2-(4-CHLOROPHENOXY)-3-PHENYLPROPANOIC ACID	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	(8E,10S,12Z)-10-HYDROXY-6-OXOOCTADECA-8,12-DIENOIC ACID	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	(8R,9Z,12Z)-8-HYDROXY-6-OXOOCTADECA-9,12-DIENOIC ACID	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	MITIGLINIDE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TROGLITAZONE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	SB-219993	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	INDOMETHACIN	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	LY-465608	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	GW1929	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	DICLOFENAC	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	REGLITAZAR	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	LY-510929	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	LINOLEIC ACID	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	NTZDPA	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	CIGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	FMOC-L-LEUCINE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	GW7845	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	L-796449	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PAT5A	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	FARGLITAZAR	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TROGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	RAGAGLITAZAR	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	L-764406	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	AD-5061	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	GW0072	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	SB-219994	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	GW9662	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	BARDOXOLONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TROGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	NETOGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	NETOGLITAZONE	agonist	TTD	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	GENISTEIN	agonist	TTD	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE & SIMVASTATIN	agonist	TTD	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TROGLITAZONE	agonist	TTD	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE	agonist	TTD	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	OLANZAPINE	n/a	PharmGKB	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ZOLEDRONATE	n/a	PharmGKB	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	MURAGLITAZAR	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ALEGLITAZAR	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	METAGLIDASEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	NAVEGLITAZAR	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	BALSALAZIDE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	SULFASALAZINE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TREPROSTINIL	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	n/a	TEND	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TREPROSTINIL	n/a	TEND	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE	n/a	TEND	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	OLSALAZINE SODIUM	agonist	ChEMBL	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE HYDROCHLORIDE	agonist	ChEMBL	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	BALSALAZIDE DISODIUM	agonist	ChEMBL	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE MALEATE	agonist	ChEMBL	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TROGLITAZONE	agonist	ChEMBL	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	EFATUTAZONE	agonist	TALC	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	(5R,6E,8Z,11Z,14Z,17Z)-5-HYDROXYICOSA-6,8,11,14,17-PENTAENOIC ACID	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	SULFASALAZINE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	INDOMETHACIN	activator	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ALEGLITAZAR	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	REPAGLINIDE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	(2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	BALSALAZIDE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	DIFLUORO(5-{2-[(5-OCTYL-1H-PYRROL-2-YL-KAPPAN)METHYLIDENE]-2H-PYRROL-5-YL-KAPPAN}PENTANOATO)BORON	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	NATEGLINIDE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	IBUPROFEN	activator	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	(4S,5E,7Z,10Z,13Z,16Z,19Z)-4-HYDROXYDOCOSA-5,7,10,13,16,19-HEXAENOIC ACID	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	GLIPIZIDE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TELMISARTAN	partial agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	T131	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	BEZAFIBRATE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	(2S)-2-(4-CHLOROPHENOXY)-3-PHENYLPROPANOIC ACID	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	(8E,10S,12Z)-10-HYDROXY-6-OXOOCTADECA-8,12-DIENOIC ACID	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	(8R,9Z,12Z)-8-HYDROXY-6-OXOOCTADECA-9,12-DIENOIC ACID	n/a	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	MITIGLINIDE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TROGLITAZONE	agonist	DrugBank	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	SB-219993	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	INDOMETHACIN	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	LY-465608	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	GW1929	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	DICLOFENAC	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	REGLITAZAR	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	LY-510929	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	LINOLEIC ACID	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	NTZDPA	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	CIGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	FMOC-L-LEUCINE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	GW7845	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	L-796449	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PAT5A	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	FARGLITAZAR	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TROGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	RAGAGLITAZAR	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	L-764406	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	AD-5061	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	GW0072	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	SB-219994	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	GW9662	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	BARDOXOLONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TROGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	NETOGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	NETOGLITAZONE	agonist	TTD	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	GENISTEIN	agonist	TTD	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE & SIMVASTATIN	agonist	TTD	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TROGLITAZONE	agonist	TTD	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE	agonist	TTD	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	OLANZAPINE	n/a	PharmGKB	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ZOLEDRONATE	n/a	PharmGKB	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	MURAGLITAZAR	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ALEGLITAZAR	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	METAGLIDASEN	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	NAVEGLITAZAR	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	BALSALAZIDE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	SULFASALAZINE	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TREPROSTINIL	n/a	TdgClinicalTrial	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE	n/a	TEND	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TREPROSTINIL	n/a	TEND	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE	n/a	TEND	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	OLSALAZINE SODIUM	agonist	ChEMBL	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	PIOGLITAZONE HYDROCHLORIDE	agonist	ChEMBL	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	BALSALAZIDE DISODIUM	agonist	ChEMBL	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	ROSIGLITAZONE MALEATE	agonist	ChEMBL	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	TROGLITAZONE	agonist	ChEMBL	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
PPARG	EFATUTAZONE	agonist	TALC	drug resistance,druggable genome,g protein coupled receptor,nuclear hormone receptor,transcription factor binding,transcription factor complex
SULT1A1	ADENOSINE-3'-5'-DIPHOSPHATE	n/a	DrugBank	
SULT1A1	ACETAMINOPHEN	n/a	PharmGKB	
AQP9	PHLORETIN	n/a	GuideToPharmacologyInteractions	transporter
AQP9	PHLORETIN	n/a	GuideToPharmacologyInteractions	transporter
XBP1	VALPROIC ACID	n/a	PharmGKB	drug resistance,transcription factor binding
VCAM1	CARVEDILOL	inhibitor	DrugBank	cell surface,external side of plasma membrane
VCAM1	ETHANOL	n/a	DrugBank	cell surface,external side of plasma membrane
LCN2	2,3,-DIHYDROXYBENZOYLSERINE	n/a	DrugBank	drug resistance,transporter
LCN2	CARBOXYMYCOBACTIN T	n/a	DrugBank	drug resistance,transporter
LCN2	CARBOXYMYCOBACTIN S	n/a	DrugBank	drug resistance,transporter
LCN2	2,3,-DIHYDROXYBENZOYLSERINE	n/a	DrugBank	drug resistance,transporter
LCN2	CARBOXYMYCOBACTIN T	n/a	DrugBank	drug resistance,transporter
LCN2	CARBOXYMYCOBACTIN S	n/a	DrugBank	drug resistance,transporter
GPX2	GLUTATHIONE	cofactor	DrugBank	druggable genome
CCND2	LY2835219	n/a	ClearityFoundationBiomarkers	clinically actionable,tumor suppressor
CCND2	LEE011	n/a	ClearityFoundationBiomarkers	clinically actionable,tumor suppressor
S100A11	PHOSPHONOTHREONINE	n/a	DrugBank	
ATR	VELIPARIB	n/a	ClearityFoundationBiomarkers	clinically actionable,dna repair,drug resistance,druggable genome,kinase,phosphatidylinositol 3 kinase,serine threonine kinase
ATR	RUCAPARIB	n/a	ClearityFoundationBiomarkers	clinically actionable,dna repair,drug resistance,druggable genome,kinase,phosphatidylinositol 3 kinase,serine threonine kinase
ATR	BMN673	n/a	ClearityFoundationBiomarkers	clinically actionable,dna repair,drug resistance,druggable genome,kinase,phosphatidylinositol 3 kinase,serine threonine kinase
ATR	OLAPARIB	n/a	ClearityFoundationBiomarkers	clinically actionable,dna repair,drug resistance,druggable genome,kinase,phosphatidylinositol 3 kinase,serine threonine kinase
ATR	VELIPARIB	n/a	ClearityFoundationBiomarkers	clinically actionable,dna repair,drug resistance,druggable genome,kinase,phosphatidylinositol 3 kinase,serine threonine kinase
ATR	RUCAPARIB	n/a	ClearityFoundationBiomarkers	clinically actionable,dna repair,drug resistance,druggable genome,kinase,phosphatidylinositol 3 kinase,serine threonine kinase
ATR	BMN673	n/a	ClearityFoundationBiomarkers	clinically actionable,dna repair,drug resistance,druggable genome,kinase,phosphatidylinositol 3 kinase,serine threonine kinase
ATR	OLAPARIB	n/a	ClearityFoundationBiomarkers	clinically actionable,dna repair,drug resistance,druggable genome,kinase,phosphatidylinositol 3 kinase,serine threonine kinase
KCND3	FLUNARIZINE	blocker	TTD	druggable genome,ion channel,transporter
KCND3	IMIPRAMINE	inhibitor	DrugBank	druggable genome,ion channel,transporter
KCND3	AMITRIPTYLINE	inhibitor	DrugBank	druggable genome,ion channel,transporter
KCND3	DISOPYRAMIDE	inhibitor	DrugBank	druggable genome,ion channel,transporter
KCND3	FLUNARIZINE	blocker	TTD	druggable genome,ion channel,transporter
KCND3	IMIPRAMINE	inhibitor	DrugBank	druggable genome,ion channel,transporter
KCND3	AMITRIPTYLINE	inhibitor	DrugBank	druggable genome,ion channel,transporter
KCND3	DISOPYRAMIDE	inhibitor	DrugBank	druggable genome,ion channel,transporter
CXCL10	N-METHYLLEUCINE	n/a	DrugBank	cell surface,external side of plasma membrane
CXCL10	N-METHYLLEUCINE	n/a	DrugBank	cell surface,external side of plasma membrane
STAT3	RTA 402	inhibitor	TTD	drug resistance,nuclear hormone receptor,transcription factor binding,transcription factor complex
STAT3	ATIPRIMOD	inhibitor	TTD	drug resistance,nuclear hormone receptor,transcription factor binding,transcription factor complex
PIM2	RUBOXISTAURIN	n/a	GuideToPharmacologyInteractions	druggable genome,kinase,serine threonine kinase,tumor suppressor
PIM2	AZD1208	n/a	GuideToPharmacologyInteractions	druggable genome,kinase,serine threonine kinase,tumor suppressor
PIM2	SGI-1776	n/a	TdgClinicalTrial	druggable genome,kinase,serine threonine kinase,tumor suppressor
PIM2	RUBOXISTAURIN	n/a	GuideToPharmacologyInteractions	druggable genome,kinase,serine threonine kinase,tumor suppressor
PIM2	AZD1208	n/a	GuideToPharmacologyInteractions	druggable genome,kinase,serine threonine kinase,tumor suppressor
PIM2	SGI-1776	n/a	TdgClinicalTrial	druggable genome,kinase,serine threonine kinase,tumor suppressor
F3	2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE	n/a	DrugBank	cell surface,external side of plasma membrane
F3	[2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA	n/a	DrugBank	cell surface,external side of plasma membrane
LYZ	L-ASPARTIC ACID	n/a	DrugBank	
LYZ	DODECYL SULFATE	n/a	DrugBank	
LYZ	METHYLUMBELLIFERYL CHITOTRIOSE	n/a	DrugBank	
LYZ	3-AMINOSUCCINIMIDE	n/a	DrugBank	
LYZ	4-METHYLUMBELLIFERYL CHITOBIOSE	n/a	DrugBank	
LYZ	DI(N-ACETYL-D-GLUCOSAMINE)	n/a	DrugBank	
LYZ	CU-CYCLAM	n/a	DrugBank	
LYZ	UNDECA-3,7-DIENE-1,3,7,11-TETRACARBALDEHYDE	n/a	DrugBank	
PAICS	L-ASPARTIC ACID	n/a	DrugBank	
GJA1	FLUFENAMIC ACID	n/a	GuideToPharmacologyInteractions	transporter
GJA1	CARBENOXOLONE	n/a	GuideToPharmacologyInteractions	transporter
GJA1	CARVEDILOL	other/unknown	DrugBank	transporter
ACSL1	ADENOSINE TRIPHOSPHATE	n/a	DrugBank	drug resistance
CCR1	UCB35625	n/a	GuideToPharmacologyInteractions	cell surface,druggable genome,external side of plasma membrane,g protein coupled receptor,phospholipase
CCR1	UCB35625	n/a	GuideToPharmacologyInteractions	cell surface,druggable genome,external side of plasma membrane,g protein coupled receptor,phospholipase
ADH1A	4-IODOPYRAZOLE	n/a	DrugBank	drug metabolism,druggable genome
ADH1A	ETHANOL	n/a	PharmGKB	drug metabolism,druggable genome
LDHB	OXAMIC ACID	n/a	DrugBank	
ME1	2'-MONOPHOSPHOADENOSINE 5'-DIPHOSPHORIBOSE	n/a	DrugBank	
SLC16A1	PYRUVIC ACID	n/a	DrugBank	druggable genome,transporter
SLC16A1	PYRUVIC ACID	n/a	DrugBank	druggable genome,transporter
PSMD10	CARFILZOMIB	other/unknown	MyCancerGenome	transcription factor binding,tumor suppressor
PSMD10	BORTEZOMIB	other/unknown	MyCancerGenome	transcription factor binding,tumor suppressor
PSME4	CARFILZOMIB	other/unknown	MyCancerGenome	dna repair,tumor suppressor
PSME4	BORTEZOMIB	other/unknown	MyCancerGenome	dna repair,tumor suppressor
GARS	GLYCINE	n/a	DrugBank	
GPR183	25-HYDROXYCHOLESTEROL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
GPR183	27-HYDROXYCHOLESTEROL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
MAOA	PHENELZINE	n/a	TdgClinicalTrial	druggable genome
MAOA	MOCLOBEMIDE	n/a	TdgClinicalTrial	druggable genome
MAOA	ISOCARBOXAZID	n/a	TdgClinicalTrial	druggable genome
MAOA	METHAMPHETAMINE	n/a	TdgClinicalTrial	druggable genome
MAOA	CX157	n/a	TdgClinicalTrial	druggable genome
MAOA	TRANYLCYPROMINE	n/a	TdgClinicalTrial	druggable genome
MAOA	ISOCARBOXAZID	n/a	TEND	druggable genome
MAOA	PHENELZINE	n/a	TEND	druggable genome
MAOA	TRANYLCYPROMINE	n/a	TEND	druggable genome
MAOA	MOCLOBEMIDE	n/a	TEND	druggable genome
MAOA	PHENTERMINE	antagonist	DrugBank	druggable genome
MAOA	ZONISAMIDE	inhibitor	DrugBank	druggable genome
MAOA	METHAMPHETAMINE	inhibitor	DrugBank	druggable genome
MAOA	CX157	n/a	DrugBank	druggable genome
MAOA	TRANYLCYPROMINE	inhibitor	DrugBank	druggable genome
MAOA	MOCLOBEMIDE	inhibitor	DrugBank	druggable genome
MAOA	MINAPRINE	inhibitor	DrugBank	druggable genome
MAOA	ISOCARBOXAZID	inhibitor	DrugBank	druggable genome
MAOA	SELEGILINE	inhibitor	DrugBank	druggable genome
MAOA	4-METHOXYAMPHETAMINE	inhibitor	DrugBank	druggable genome
MAOA	NOMIFENSINE	n/a	DrugBank	druggable genome
MAOA	PHENELZINE	antagonist	DrugBank	druggable genome
MAOA	MMDA	inhibitor	DrugBank	druggable genome
MAOA	ZIMELIDINE	inhibitor	DrugBank	druggable genome
MAOA	NIALAMIDE	n/a	DrugBank	druggable genome
MAOA	PARGYLINE	inhibitor	DrugBank	druggable genome
MAOA	PROCAINE	n/a	DrugBank	druggable genome
MAOA	SELEGILINE	n/a	GuideToPharmacologyInteractions	druggable genome
MAOA	PHENELZINE	n/a	GuideToPharmacologyInteractions	druggable genome
MAOA	MOCLOBEMIDE	n/a	GuideToPharmacologyInteractions	druggable genome
MAOA	PIRLINDOLE	n/a	GuideToPharmacologyInteractions	druggable genome
MAOA	CLORGILINE	n/a	GuideToPharmacologyInteractions	druggable genome
MAOA	BEFLOXATONE	n/a	GuideToPharmacologyInteractions	druggable genome
MAOA	TRANYLCYPROMINE	n/a	GuideToPharmacologyInteractions	druggable genome
GLYAT	GLYCINE	n/a	DrugBank	
TNFRSF11B	ZOLEDRONATE	n/a	PharmGKB	drug resistance
MMP7	MARIMASTAT	inhibitor	TTD	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	BATIMASTAT	inhibitor	TTD	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	BMS 275291	inhibitor	TTD	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	PRINOMASTAT	inhibitor	TTD	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	(1R)-N,6-DIHYDROXY-7-METHOXY-2-[(4-METHOXYPHENYL)SULFONYL]-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXAMIDE	n/a	DrugBank	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	MARIMASTAT	antagonist	DrugBank	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	DOXYCYCLINE HYDRATE	inhibitor	ChEMBL	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	DOXYCYCLINE CALCIUM	inhibitor	ChEMBL	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	DOXYCYCLINE HYCLATE	inhibitor	ChEMBL	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	MARIMASTAT	inhibitor	TTD	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	BATIMASTAT	inhibitor	TTD	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	BMS 275291	inhibitor	TTD	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	PRINOMASTAT	inhibitor	TTD	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	(1R)-N,6-DIHYDROXY-7-METHOXY-2-[(4-METHOXYPHENYL)SULFONYL]-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXAMIDE	n/a	DrugBank	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	MARIMASTAT	antagonist	DrugBank	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	DOXYCYCLINE HYDRATE	inhibitor	ChEMBL	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	DOXYCYCLINE CALCIUM	inhibitor	ChEMBL	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP7	DOXYCYCLINE HYCLATE	inhibitor	ChEMBL	cell surface,drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP9	METHYLDOPA	n/a	PharmGKB	druggable genome,neutral zinc metallopeptidase,protease
MMP9	NIFEDIPINE	n/a	PharmGKB	druggable genome,neutral zinc metallopeptidase,protease
MMP9	PG-116800	inhibitor	TTD	druggable genome,neutral zinc metallopeptidase,protease
MMP9	MARIMASTAT	n/a	TEND	druggable genome,neutral zinc metallopeptidase,protease
MMP9	MARIMASTAT	n/a	TdgClinicalTrial	druggable genome,neutral zinc metallopeptidase,protease
NME1	3'-AZIDO-3'-DEOXYTHYMIDINE-5'-DIPHOSPHATE	n/a	DrugBank	drug resistance,kinase
NME1	FUDP	n/a	DrugBank	drug resistance,kinase
NME1	SELENOCYSTEINE	n/a	DrugBank	drug resistance,kinase
NME1	3'-DEOXY 3'-AMINO ADENOSINE-5'-DIPHOSPHATE	n/a	DrugBank	drug resistance,kinase
NME1	2'-DEOXYGUANOSINE-5'-TRIPHOSPHATE	n/a	DrugBank	drug resistance,kinase
NME1	THYMIDINE-5'- DIPHOSPHATE	n/a	DrugBank	drug resistance,kinase
NME1	3'-AZIDO-3'-DEOXYTHYMIDINE-5'-DIPHOSPHATE	n/a	DrugBank	drug resistance,kinase
NME1	FUDP	n/a	DrugBank	drug resistance,kinase
NME1	SELENOCYSTEINE	n/a	DrugBank	drug resistance,kinase
NME1	3'-DEOXY 3'-AMINO ADENOSINE-5'-DIPHOSPHATE	n/a	DrugBank	drug resistance,kinase
NME1	2'-DEOXYGUANOSINE-5'-TRIPHOSPHATE	n/a	DrugBank	drug resistance,kinase
NME1	THYMIDINE-5'- DIPHOSPHATE	n/a	DrugBank	drug resistance,kinase
VIPR1	HELODERMIN	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
VIPR1	HELODERMIN	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
VIPR1	[ALA<SUP>11,22,28</SUP>]VIP	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
VIPR1	[ALA<SUP>11,22,28</SUP>]VIP	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
VIPR1	[ALA<SUP>11,22,28</SUP>]VIP	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
VIPR1	[ALA<SUP>11,22,28</SUP>]VIP	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
VIPR1	HELODERMIN	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
VIPR1	HELODERMIN	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
VIPR1	[ALA<SUP>11,22,28</SUP>]VIP	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
VIPR1	[ALA<SUP>11,22,28</SUP>]VIP	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
VIPR1	[ALA<SUP>11,22,28</SUP>]VIP	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
VIPR1	[ALA<SUP>11,22,28</SUP>]VIP	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
IARS	L-ISOLEUCINE	n/a	DrugBank	druggable genome
PLA2G2A	4-(1-BENZYL-3-CARBAMOYLMETHYL-2-METHYL-1H-INDOL-5-YLOXY)-BUTYRIC ACID	n/a	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	SURAMIN	inhibitor	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	INDOMETHACIN	inhibitor	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	1-OCTADECYL-2-ACETAMIDO-2-DEOXY-SN-GLYCEROL-3-PHOSPHOETHYLMETHYL SULFIDE	n/a	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	DICLOFENAC	inhibitor	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	1,4-BUTANEDIOL	n/a	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	6-PHENYL-4(R)-(7-PHENYL-HEPTANOYLAMINO)-HEXANOIC ACID	n/a	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	VARESPLADIB	inhibitor	TTD	druggable genome,lipase,phospholipase
PLA2G2A	VARESPLADIB	n/a	TdgClinicalTrial	druggable genome,lipase,phospholipase
PLA2G2A	VARESPLADIB	n/a	TdgClinicalTrial	druggable genome,lipase,phospholipase
PLA2G2A	4-(1-BENZYL-3-CARBAMOYLMETHYL-2-METHYL-1H-INDOL-5-YLOXY)-BUTYRIC ACID	n/a	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	SURAMIN	inhibitor	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	INDOMETHACIN	inhibitor	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	1-OCTADECYL-2-ACETAMIDO-2-DEOXY-SN-GLYCEROL-3-PHOSPHOETHYLMETHYL SULFIDE	n/a	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	DICLOFENAC	inhibitor	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	1,4-BUTANEDIOL	n/a	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	6-PHENYL-4(R)-(7-PHENYL-HEPTANOYLAMINO)-HEXANOIC ACID	n/a	DrugBank	druggable genome,lipase,phospholipase
PLA2G2A	VARESPLADIB	inhibitor	TTD	druggable genome,lipase,phospholipase
PLA2G2A	VARESPLADIB	n/a	TdgClinicalTrial	druggable genome,lipase,phospholipase
PLA2G2A	VARESPLADIB	n/a	TdgClinicalTrial	druggable genome,lipase,phospholipase
CCND1	LY2835219	n/a	ClearityFoundationBiomarkers	clinically actionable,drug resistance,kinase,transcription factor binding,tumor suppressor
CCND1	LEE011	n/a	ClearityFoundationBiomarkers	clinically actionable,drug resistance,kinase,transcription factor binding,tumor suppressor
CCND1	TAMOXIFEN	n/a	CIViC	clinically actionable,drug resistance,kinase,transcription factor binding,tumor suppressor
CCND1	LY2835219	n/a	ClearityFoundationBiomarkers	clinically actionable,drug resistance,kinase,transcription factor binding,tumor suppressor
CCND1	LEE011	n/a	ClearityFoundationBiomarkers	clinically actionable,drug resistance,kinase,transcription factor binding,tumor suppressor
CCND1	TAMOXIFEN	n/a	CIViC	clinically actionable,drug resistance,kinase,transcription factor binding,tumor suppressor
GLUL	L-GLUTAMIC ACID	n/a	DrugBank	
GLUL	L-GLUTAMINE	product of	DrugBank	
AHR	MEXILETINE	agonist	DrugBank	nuclear hormone receptor,transcription factor binding,transcription factor complex
AHR	FLUTAMIDE	agonist	DrugBank	nuclear hormone receptor,transcription factor binding,transcription factor complex
AHR	LEFLUNOMIDE	agonist	DrugBank	nuclear hormone receptor,transcription factor binding,transcription factor complex
AHR	ATORVASTATIN	agonist	DrugBank	nuclear hormone receptor,transcription factor binding,transcription factor complex
AHR	NIMODIPINE	agonist	DrugBank	nuclear hormone receptor,transcription factor binding,transcription factor complex
ASS1	SODIUM BENZOATE	n/a	PharmGKB	drug resistance
ASS1	ADENOSINE TRIPHOSPHATE	n/a	DrugBank	drug resistance
ASS1	L-ASPARTIC ACID	n/a	DrugBank	drug resistance
ASS1	L-CITRULLINE	n/a	DrugBank	drug resistance
ASS1	L-ARGININE	n/a	DrugBank	drug resistance
ASS1	L-ASPARTIC ACID	n/a	DrugBank	drug resistance
ASS1	L-CITRULLINE	n/a	DrugBank	drug resistance
CASP1	VX-765	n/a	DrugBank	druggable genome,protease
CASP1	3-{6-[(8-HYDROXY-QUINOLINE-2-CARBONYL)-AMINO]-2-THIOPHEN-2-YL-HEXANOYLAMINO}-4-OXO-BUTYRI ACID	n/a	DrugBank	druggable genome,protease
CASP1	MINOCYCLINE	negative modulator	DrugBank	druggable genome,protease
CASP1	PRALNACASAN	n/a	DrugBank	druggable genome,protease
CASP1	3-[2-(2-BENZYLOXYCARBONYLAMINO-3-METHYL-BUTYRYLAMINO)-PROPIONYLAMINO]-4-OXO-PENTANOIC ACID	n/a	DrugBank	druggable genome,protease
CASP1	1-METHYL-3-TRIFLUOROMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE	n/a	DrugBank	druggable genome,protease
CASP1	Z-YVAD-FMK	n/a	GuideToPharmacologyInteractions	druggable genome,protease
CASP1	PRALNACASAN	n/a	GuideToPharmacologyInteractions	druggable genome,protease
CASP1	VX-765	n/a	TdgClinicalTrial	druggable genome,protease
CASP1	VX-765	n/a	DrugBank	druggable genome,protease
CASP1	3-{6-[(8-HYDROXY-QUINOLINE-2-CARBONYL)-AMINO]-2-THIOPHEN-2-YL-HEXANOYLAMINO}-4-OXO-BUTYRI ACID	n/a	DrugBank	druggable genome,protease
CASP1	MINOCYCLINE	negative modulator	DrugBank	druggable genome,protease
CASP1	PRALNACASAN	n/a	DrugBank	druggable genome,protease
CASP1	3-[2-(2-BENZYLOXYCARBONYLAMINO-3-METHYL-BUTYRYLAMINO)-PROPIONYLAMINO]-4-OXO-PENTANOIC ACID	n/a	DrugBank	druggable genome,protease
CASP1	1-METHYL-3-TRIFLUOROMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE	n/a	DrugBank	druggable genome,protease
CASP1	Z-YVAD-FMK	n/a	GuideToPharmacologyInteractions	druggable genome,protease
CASP1	PRALNACASAN	n/a	GuideToPharmacologyInteractions	druggable genome,protease
CASP1	VX-765	n/a	TdgClinicalTrial	druggable genome,protease
CDK1	DINACICLIB	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	BOHEMINE	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	AMINOPURVALANOL A	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	CDK1/5 INHIBITOR	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	ALSTERPAULLONE	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	AURORA KINASE/CDK INHIBITOR	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	ALOISINE A	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	RONICICLIB	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	CDK1 INHIBITOR	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	SU9516	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	CDK4 INHIBITOR	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	CDK1/2 INHIBITOR III	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	RGB-286638	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	OLOMOUCINE	binder	DrugBank	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	AT7519	n/a	DrugBank	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	HYMENIALDISINE	n/a	DrugBank	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	INDIRUBIN-3'-MONOXIME	binder	DrugBank	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	SU9516	binder	DrugBank	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	ALSTERPAULLONE	inhibitor	DrugBank	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	DINACICLIB	n/a	ClearityFoundationClinicalTrial	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	DINACICLIB	n/a	ClearityFoundationClinicalTrial	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	DINACICLIB	inhibitor	MyCancerGenome	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	ALVOCIDIB	inhibitor	MyCancerGenome	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	DINACICLIB	inhibitor	MyCancerGenomeClinicalTrial	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	DINACICLIB	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	BOHEMINE	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	AMINOPURVALANOL A	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	CDK1/5 INHIBITOR	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	ALSTERPAULLONE	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	AURORA KINASE/CDK INHIBITOR	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	ALOISINE A	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	RONICICLIB	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	CDK1 INHIBITOR	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	SU9516	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	CDK4 INHIBITOR	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	CDK1/2 INHIBITOR III	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	RGB-286638	n/a	GuideToPharmacologyInteractions	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	OLOMOUCINE	binder	DrugBank	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	AT7519	n/a	DrugBank	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	HYMENIALDISINE	n/a	DrugBank	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	INDIRUBIN-3'-MONOXIME	binder	DrugBank	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	SU9516	binder	DrugBank	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	ALSTERPAULLONE	inhibitor	DrugBank	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	DINACICLIB	n/a	ClearityFoundationClinicalTrial	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	DINACICLIB	n/a	ClearityFoundationClinicalTrial	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	DINACICLIB	inhibitor	MyCancerGenome	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	ALVOCIDIB	inhibitor	MyCancerGenome	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
CDK1	DINACICLIB	inhibitor	MyCancerGenomeClinicalTrial	dna repair,druggable genome,kinase,serine threonine kinase,tumor suppressor
MMP12	N-OXO-2-[(4-PHENYLPHENYL)SULFONYLAMINO]ETHANAMIDE	n/a	DrugBank	drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP12	2-[(4-FLUOROPHENYL)SULFONYLAMINO]-N-OXO-ETHANAMIDE	n/a	DrugBank	drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP12	N-(BIPHENYL-4-YLSULFONYL)-D-LEUCINE	n/a	DrugBank	drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP12	MARIMASTAT	inhibitor	DrugBank	drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP12	CP-271485	n/a	DrugBank	drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP12	N-(DIBENZO[B,D]THIOPHEN-3-YLSULFONYL)-L-VALINE	n/a	DrugBank	drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP12	BATIMASTAT	n/a	DrugBank	drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP12	ACETOHYDROXAMIC ACID	inhibitor	DrugBank	drug resistance,druggable genome,neutral zinc metallopeptidase,protease
MMP12	AZD1236	inhibitor	TTD	drug resistance,druggable genome,neutral zinc metallopeptidase,protease
GLRX	GLUTATHIONE	n/a	DrugBank	
SLC1A1	CLOZAPINE	n/a	PharmGKB	transporter
SLC1A1	RISPERIDONE	n/a	PharmGKB	transporter
SLC1A1	OLANZAPINE	n/a	PharmGKB	transporter
SLC1A1	DL-TBOA	n/a	GuideToPharmacologyInteractions	transporter
SLC1A1	L-GLUTAMIC ACID	n/a	DrugBank	transporter
SLC1A1	L-ASPARTIC ACID	n/a	DrugBank	transporter
SLC1A1	CLOZAPINE	n/a	PharmGKB	transporter
SLC1A1	RISPERIDONE	n/a	PharmGKB	transporter
SLC1A1	OLANZAPINE	n/a	PharmGKB	transporter
SLC1A1	DL-TBOA	n/a	GuideToPharmacologyInteractions	transporter
SLC1A1	L-GLUTAMIC ACID	n/a	DrugBank	transporter
SLC1A1	L-ASPARTIC ACID	n/a	DrugBank	transporter
PSMB9	CARFILZOMIB	other/unknown	MyCancerGenome	druggable genome,protease,tumor suppressor
PSMB9	BORTEZOMIB	other/unknown	MyCancerGenome	druggable genome,protease,tumor suppressor
PSMB9	CARFILZOMIB	inhibitor	DrugBank	druggable genome,protease,tumor suppressor
PSMB9	CARFILZOMIB	other/unknown	MyCancerGenome	druggable genome,protease,tumor suppressor
PSMB9	BORTEZOMIB	other/unknown	MyCancerGenome	druggable genome,protease,tumor suppressor
PSMB9	CARFILZOMIB	inhibitor	DrugBank	druggable genome,protease,tumor suppressor
ATP2A2	ISTAROXIME	n/a	TdgClinicalTrial	abc transporter,druggable genome,transporter
ATP2A2	ISTAROXIME	n/a	TdgClinicalTrial	abc transporter,druggable genome,transporter
ANXA3	ETHANOLAMINE	n/a	DrugBank	
AASS	L-GLUTAMIC ACID	n/a	DrugBank	
PSMA3	(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE	n/a	DrugBank	druggable genome,protease,tumor suppressor
PSMA3	BORTEZOMIB	other/unknown	MyCancerGenome	druggable genome,protease,tumor suppressor
PSMA3	CARFILZOMIB	other/unknown	MyCancerGenome	druggable genome,protease,tumor suppressor
PSMA3	(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE	n/a	DrugBank	druggable genome,protease,tumor suppressor
PSMA3	BORTEZOMIB	other/unknown	MyCancerGenome	druggable genome,protease,tumor suppressor
PSMA3	CARFILZOMIB	other/unknown	MyCancerGenome	druggable genome,protease,tumor suppressor
PGK1	3-PHOSPHOGLYCERIC ACID	n/a	DrugBank	kinase
PGK1	ADENOSINE-5'-[BETA, GAMMA-METHYLENE]TRIPHOSPHATE	n/a	DrugBank	kinase
XDH	DIOXOTHIOMOLYBDENUM(VI) ION	n/a	DrugBank	
XDH	L-CARNITINE	n/a	DrugBank	
XDH	ALLOPURINOL	inhibitor	DrugBank	
XDH	OXYPURINOL	n/a	DrugBank	
XDH	ENILURACIL	inhibitor	DrugBank	
XDH	ALLOPURINOL	n/a	GuideToPharmacologyInteractions	
XDH	ALLOPURINOL	n/a	GuideToPharmacologyInteractions	
XDH	ALLOPURINOL SODIUM	inhibitor	ChEMBL	
XDH	FEBUXOSTAT	inhibitor	ChEMBL	
XDH	ALLOPURINOL	inhibitor	ChEMBL	
XDH	FEBUXOSTAT	inhibitor	TTD	
XDH	FEBUXOSTAT	n/a	TdgClinicalTrial	
XDH	ALLOPURINOL	n/a	TdgClinicalTrial	
XDH	OXYPURINOL	n/a	TdgClinicalTrial	
XDH	ALLOPURINOL	n/a	TdgClinicalTrial	
XDH	FEBUXOSTAT	n/a	TEND	
XDH	ALLOPURINOL	n/a	TEND	
PSMD14	BORTEZOMIB	other/unknown	MyCancerGenome	dna repair,druggable genome,neutral zinc metallopeptidase,protease,tumor suppressor
PSMD14	CARFILZOMIB	other/unknown	MyCancerGenome	dna repair,druggable genome,neutral zinc metallopeptidase,protease,tumor suppressor
CES2	CAPECITABINE	n/a	PharmGKB	druggable genome
CES1	CYCLANDELATE	n/a	DrugBank	druggable genome
CES1	(1R)-1,2,2-TRIMETHYLPROPYL (R)-METHYLPHOSPHINATE	n/a	DrugBank	druggable genome
CES1	N-METHYLNALOXONIUM	n/a	DrugBank	druggable genome
CES1	PROBUCOL	n/a	DrugBank	druggable genome
CES1	(1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HY DROXY-6-OXO-2H-PYRAN-2-YL]ETHYL]-1-NAPHTHALENOL	n/a	DrugBank	druggable genome
CES1	L-CARNITINE	n/a	DrugBank	druggable genome
CES1	O-SIALIC ACID	n/a	DrugBank	druggable genome
CES1	OSELTAMIVIR	other/unknown	DrugBank	druggable genome
CES1	CHOLIC ACID	n/a	DrugBank	druggable genome
CES1	ISONIAZID	n/a	PharmGKB	druggable genome
CES1	CAPECITABINE	n/a	PharmGKB	druggable genome
BIRC3	AT-406	n/a	GuideToPharmacologyInteractions	protease inhibitor
BIRC3	AZD5582	n/a	GuideToPharmacologyInteractions	protease inhibitor
BIRC3	SM-337	n/a	GuideToPharmacologyInteractions	protease inhibitor
BIRC3	GDC-0152	n/a	GuideToPharmacologyInteractions	protease inhibitor
BIRC3	LCL161	antagonist	TALC	protease inhibitor
BIRC3	AT-406	antagonist	TALC	protease inhibitor
BIRC3	AT-406	n/a	GuideToPharmacologyInteractions	protease inhibitor
BIRC3	AZD5582	n/a	GuideToPharmacologyInteractions	protease inhibitor
BIRC3	SM-337	n/a	GuideToPharmacologyInteractions	protease inhibitor
BIRC3	GDC-0152	n/a	GuideToPharmacologyInteractions	protease inhibitor
BIRC3	LCL161	antagonist	TALC	protease inhibitor
BIRC3	AT-406	antagonist	TALC	protease inhibitor
DPYD	5-IODOURACIL	n/a	DrugBank	druggable genome
DPYD	(5S)-5-IODODIHYDRO-2,4(1H,3H)-PYRIMIDINEDIONE	n/a	DrugBank	druggable genome
DPYD	URACIL	n/a	DrugBank	druggable genome
DPYD	ENILURACIL	n/a	DrugBank	druggable genome
DPYD	RIBOFLAVIN MONOPHOSPHATE	n/a	DrugBank	druggable genome
DPYD	6-CARBOXYMETHYLURACIL	n/a	DrugBank	druggable genome
DPYD	MITOMYCIN	n/a	PharmGKB	druggable genome
DPYD	CAPECITABINE	n/a	PharmGKB	druggable genome
DPYD	TEGAFUR	n/a	PharmGKB	druggable genome
DPYD	RALTITREXED	n/a	PharmGKB	druggable genome
DPYD	ENILURACIL	n/a	TdgClinicalTrial	druggable genome
NR1H4	22R-HYDROXYCHOLESTEROL	n/a	GuideToPharmacologyInteractions	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	OBETICHOLIC ACID	n/a	GuideToPharmacologyInteractions	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	FEXARAMINE	n/a	GuideToPharmacologyInteractions	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	CHENODEOXYCHOLIC ACID	n/a	GuideToPharmacologyInteractions	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	CHENODEOXYCHOLIC ACID	other/unknown	DrugBank	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	FEXARAMINE	n/a	DrugBank	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	OBETICHOLIC ACID	n/a	TdgClinicalTrial	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	22R-HYDROXYCHOLESTEROL	n/a	GuideToPharmacologyInteractions	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	OBETICHOLIC ACID	n/a	GuideToPharmacologyInteractions	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	FEXARAMINE	n/a	GuideToPharmacologyInteractions	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	CHENODEOXYCHOLIC ACID	n/a	GuideToPharmacologyInteractions	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	CHENODEOXYCHOLIC ACID	other/unknown	DrugBank	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	FEXARAMINE	n/a	DrugBank	druggable genome,nuclear hormone receptor,transcription factor binding
NR1H4	OBETICHOLIC ACID	n/a	TdgClinicalTrial	druggable genome,nuclear hormone receptor,transcription factor binding
TYMS	PEMETREXED	n/a	ClearityFoundationBiomarkers	drug resistance,druggable genome
TYMS	CAPECITABINE	n/a	ClearityFoundationBiomarkers	drug resistance,druggable genome
TYMS	MLS003106905	n/a	ClearityFoundationClinicalTrial	drug resistance,druggable genome
TYMS	MLS003106905	n/a	ClearityFoundationClinicalTrial	drug resistance,druggable genome
TYMS	CAPECITABINE	n/a	ClearityFoundationClinicalTrial	drug resistance,druggable genome
TYMS	MLS003106905	n/a	ClearityFoundationClinicalTrial	drug resistance,druggable genome
TYMS	5-FLUOROURACIL	n/a	ClearityFoundationClinicalTrial	drug resistance,druggable genome
TYMS	CAPECITABINE	n/a	ClearityFoundationClinicalTrial	drug resistance,druggable genome
TYMS	N-(3,5-DIMETHOXYPHENYL)IMIDODICARBONIMIDIC DIAMIDE	n/a	DrugBank	drug resistance,druggable genome
TYMS	FLOXURIDINE	n/a	DrugBank	drug resistance,druggable genome
TYMS	GEMCITABINE	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	CAPECITABINE	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	LEUCOVORIN	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE	n/a	DrugBank	drug resistance,druggable genome
TYMS	TRIFLURIDINE	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	S,S-(2-HYDROXYETHYL)THIOCYSTEINE	n/a	DrugBank	drug resistance,druggable genome
TYMS	TRIMETHOPRIM	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	RALTITREXED	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	10-PROPARGYL-5,8-DIDEAZAFOLIC ACID	n/a	DrugBank	drug resistance,druggable genome
TYMS	PEMETREXED	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	FLOXURIDINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	PEMETREXED	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	PEMETREXED	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	LEUCOVORIN	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	RALTITREXED	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	TEGAFUR	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	TEGAFUR	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	RALTITREXED	n/a	TEND	drug resistance,druggable genome
TYMS	LEUCOVORIN	n/a	TEND	drug resistance,druggable genome
TYMS	FLOXURIDINE	n/a	TEND	drug resistance,druggable genome
TYMS	PEMETREXED	n/a	TEND	drug resistance,druggable genome
TYMS	FOLIC ACID	n/a	PharmGKB	drug resistance,druggable genome
TYMS	SULFASALAZINE	n/a	PharmGKB	drug resistance,druggable genome
TYMS	RALTITREXED	n/a	PharmGKB	drug resistance,druggable genome
TYMS	5-FLUOROURACIL	n/a	CIViC	drug resistance,druggable genome
TYMS	PEMETREXED	n/a	CIViC	drug resistance,druggable genome
TYMS	IRINOTECAN	n/a	CIViC	drug resistance,druggable genome
TYMS	CAPECITABINE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
TYMS	RALTITREXED	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
TYMS	PEMETREXED	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
TYMS	FLOXURIDINE	inhibitor	ChEMBL	drug resistance,druggable genome
TYMS	PEMETREXED DISODIUM	inhibitor	ChEMBL	drug resistance,druggable genome
TYMS	CAPECITABINE	inhibitor	ChEMBL	drug resistance,druggable genome
TYMS	PEMETREXED	n/a	ClearityFoundationBiomarkers	drug resistance,druggable genome
TYMS	CAPECITABINE	n/a	ClearityFoundationBiomarkers	drug resistance,druggable genome
TYMS	MLS003106905	n/a	ClearityFoundationClinicalTrial	drug resistance,druggable genome
TYMS	MLS003106905	n/a	ClearityFoundationClinicalTrial	drug resistance,druggable genome
TYMS	CAPECITABINE	n/a	ClearityFoundationClinicalTrial	drug resistance,druggable genome
TYMS	MLS003106905	n/a	ClearityFoundationClinicalTrial	drug resistance,druggable genome
TYMS	5-FLUOROURACIL	n/a	ClearityFoundationClinicalTrial	drug resistance,druggable genome
TYMS	CAPECITABINE	n/a	ClearityFoundationClinicalTrial	drug resistance,druggable genome
TYMS	N-(3,5-DIMETHOXYPHENYL)IMIDODICARBONIMIDIC DIAMIDE	n/a	DrugBank	drug resistance,druggable genome
TYMS	FLOXURIDINE	n/a	DrugBank	drug resistance,druggable genome
TYMS	GEMCITABINE	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	CAPECITABINE	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	LEUCOVORIN	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE	n/a	DrugBank	drug resistance,druggable genome
TYMS	TRIFLURIDINE	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	S,S-(2-HYDROXYETHYL)THIOCYSTEINE	n/a	DrugBank	drug resistance,druggable genome
TYMS	TRIMETHOPRIM	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	RALTITREXED	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	10-PROPARGYL-5,8-DIDEAZAFOLIC ACID	n/a	DrugBank	drug resistance,druggable genome
TYMS	PEMETREXED	inhibitor	DrugBank	drug resistance,druggable genome
TYMS	FLOXURIDINE	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	PEMETREXED	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	PEMETREXED	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	LEUCOVORIN	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	RALTITREXED	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	TEGAFUR	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	TEGAFUR	n/a	TdgClinicalTrial	drug resistance,druggable genome
TYMS	RALTITREXED	n/a	TEND	drug resistance,druggable genome
TYMS	LEUCOVORIN	n/a	TEND	drug resistance,druggable genome
TYMS	FLOXURIDINE	n/a	TEND	drug resistance,druggable genome
TYMS	PEMETREXED	n/a	TEND	drug resistance,druggable genome
TYMS	FOLIC ACID	n/a	PharmGKB	drug resistance,druggable genome
TYMS	SULFASALAZINE	n/a	PharmGKB	drug resistance,druggable genome
TYMS	RALTITREXED	n/a	PharmGKB	drug resistance,druggable genome
TYMS	5-FLUOROURACIL	n/a	CIViC	drug resistance,druggable genome
TYMS	PEMETREXED	n/a	CIViC	drug resistance,druggable genome
TYMS	IRINOTECAN	n/a	CIViC	drug resistance,druggable genome
TYMS	CAPECITABINE	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
TYMS	RALTITREXED	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
TYMS	PEMETREXED	n/a	GuideToPharmacologyInteractions	drug resistance,druggable genome
TYMS	FLOXURIDINE	inhibitor	ChEMBL	drug resistance,druggable genome
TYMS	PEMETREXED DISODIUM	inhibitor	ChEMBL	drug resistance,druggable genome
TYMS	CAPECITABINE	inhibitor	ChEMBL	drug resistance,druggable genome
PADI2	L-CITRULLINE	n/a	DrugBank	histone modification
ANPEP	ICATIBANT	inhibitor	DrugBank	cell surface,druggable genome,external side of plasma membrane,neutral zinc metallopeptidase,protease
ANPEP	EZETIMIBE	other/unknown	DrugBank	cell surface,druggable genome,external side of plasma membrane,neutral zinc metallopeptidase,protease
ANPEP	TOSEDOSTAT	inhibitor	TALC	cell surface,druggable genome,external side of plasma membrane,neutral zinc metallopeptidase,protease
ANPEP	ICATIBANT	inhibitor	DrugBank	cell surface,druggable genome,external side of plasma membrane,neutral zinc metallopeptidase,protease
ANPEP	EZETIMIBE	other/unknown	DrugBank	cell surface,druggable genome,external side of plasma membrane,neutral zinc metallopeptidase,protease
ANPEP	TOSEDOSTAT	inhibitor	TALC	cell surface,druggable genome,external side of plasma membrane,neutral zinc metallopeptidase,protease
CYP2A6	(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE	n/a	DrugBank	cytochrome p450,drug metabolism,drug resistance,druggable genome
CYP2A6	N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE	n/a	DrugBank	cytochrome p450,drug metabolism,drug resistance,druggable genome
CYP2A6	ARTESUNATE	n/a	PharmGKB	cytochrome p450,drug metabolism,drug resistance,druggable genome
CYP2A6	COUMARIN	n/a	PharmGKB	cytochrome p450,drug metabolism,drug resistance,druggable genome
CYP2A6	ARTEMISININ	n/a	PharmGKB	cytochrome p450,drug metabolism,drug resistance,druggable genome
CYP2A6	LETROZOLE	n/a	PharmGKB	cytochrome p450,drug metabolism,drug resistance,druggable genome
CYP2A6	VALPROIC ACID	n/a	PharmGKB	cytochrome p450,drug metabolism,drug resistance,druggable genome
CYP2A6	DOCETAXEL	n/a	PharmGKB	cytochrome p450,drug metabolism,drug resistance,druggable genome
CYP2A6	CAFFEINE	n/a	PharmGKB	cytochrome p450,drug metabolism,drug resistance,druggable genome
PAPSS1	GLYCEROL	n/a	DrugBank	kinase
PAPSS1	ADENOSINE-5'-PHOSPHOSULFATE	n/a	DrugBank	kinase
PAPSS1	GLYCEROL	n/a	DrugBank	kinase
PAPSS1	ADENOSINE-5'-PHOSPHOSULFATE	n/a	DrugBank	kinase
TUBA1A	CYT997	n/a	DrugBank	druggable genome
TUBA1A	2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE	n/a	DrugBank	druggable genome
TUBA1A	EPOTHILONE B	n/a	DrugBank	druggable genome
TUBA1A	MEBENDAZOLE	inhibitor	DrugBank	druggable genome
TUBA1A	ALBENDAZOLE	inhibitor	DrugBank	druggable genome
TUBA1A	VINBLASTINE	adduct	DrugBank	druggable genome
TUBA1A	MEBENDAZOLE	n/a	TdgClinicalTrial	druggable genome
MAP2	PACLITAXEL	n/a	DrugBank	
MAP2	ESTRAMUSTINE	antagonist	DrugBank	
MAP2	DOCETAXEL	n/a	DrugBank	
AREG	CRIZOTINIB	n/a	CIViC	cell surface,clinically actionable,growth factor
IL7R	RUXOLITINIB	n/a	DoCM	cell surface,clinically actionable,external side of plasma membrane
FYN	DASATINIB	inhibitor	TTD	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	ENMD-2076	n/a	TdgClinicalTrial	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	DASATINIB	n/a	TdgClinicalTrial	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	DASATINIB	n/a	TEND	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	DASATINIB	multitarget	DrugBank	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	DASATINIB	inhibitor	TTD	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	VX-680	inhibitor	TTD	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	DASATINIB	inhibitor	TTD	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	ENMD-2076	n/a	TdgClinicalTrial	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	DASATINIB	n/a	TdgClinicalTrial	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	DASATINIB	n/a	TEND	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	DASATINIB	multitarget	DrugBank	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	DASATINIB	inhibitor	TTD	drug resistance,druggable genome,kinase,tyrosine kinase
FYN	VX-680	inhibitor	TTD	drug resistance,druggable genome,kinase,tyrosine kinase
PRNP	TETRACYCLINE	inhibitor	DrugBank	cell surface,drug resistance,tumor suppressor
PRNP	TETRACYCLINE	inhibitor	DrugBank	cell surface,drug resistance,tumor suppressor
LGALS1	THIODIGALACTOSIDE	n/a	DrugBank	cell surface,drug resistance
STAT5B	DASATINIB	n/a	TEND	tumor suppressor
STAT5B	DASATINIB	n/a	TdgClinicalTrial	tumor suppressor
STAT5B	DASATINIB	inhibitor	DrugBank	tumor suppressor
TNNC2	FELODIPINE	other/unknown	DrugBank	
TNNC2	CALCIUM	agonist	DrugBank	
TNNC2	OCTYLPHENOXY POLYETHOXYETHANOL	n/a	DrugBank	
ATP6V1B2	GALLIUM NITRATE	inhibitor	DrugBank	abc transporter,transporter
ATP6V1B2	4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE	n/a	DrugBank	abc transporter,transporter
ATP6V1B2	GALLIUM NITRATE	inhibitor	DrugBank	abc transporter,transporter
ATP6V1B2	4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE	n/a	DrugBank	abc transporter,transporter
PLAUR	WX-UK1	n/a	DrugBank	kinase
F2R	VORAPAXAR	antagonist	DrugBank	cell surface,druggable genome,g protein coupled receptor
F2R	STREPTOKINASE	cleavage	DrugBank	cell surface,druggable genome,g protein coupled receptor
F2R	VORAPAXAR	n/a	TdgClinicalTrial	cell surface,druggable genome,g protein coupled receptor
F2R	RUSALATIDE	n/a	TdgClinicalTrial	cell surface,druggable genome,g protein coupled receptor
F2R	VORAPAXAR	antagonist	DrugBank	cell surface,druggable genome,g protein coupled receptor
F2R	STREPTOKINASE	cleavage	DrugBank	cell surface,druggable genome,g protein coupled receptor
F2R	VORAPAXAR	n/a	TdgClinicalTrial	cell surface,druggable genome,g protein coupled receptor
F2R	RUSALATIDE	n/a	TdgClinicalTrial	cell surface,druggable genome,g protein coupled receptor
L3MBTL1	2-(N-MORPHOLINO)-ETHANESULFONIC ACID	n/a	DrugBank	tumor suppressor
PTGER3	CLOPROSTENOL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	TREPROSTINIL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	SULPROSTONE	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	SULPROSTONE	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	FLUPROSTENOL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	L-826266	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	ENPROSTIL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	ENPROSTIL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	GR 63799	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	SC-51322	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	ILOPROST	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	CARBACYCLIN	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	ONO-AE-248	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	DG-041	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	DG-041	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	DG-041	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	ILOPROST	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	L-826266	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	L-826266	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	CLOPROSTENOL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	CICAPROST	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	DG-041	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	MISOPROSTOL	agonist	DrugBank	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	BIMATOPROST	n/a	TdgClinicalTrial	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	MISOPROSTOL	agonist	ChEMBL	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	CLOPROSTENOL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	TREPROSTINIL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	SULPROSTONE	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	SULPROSTONE	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	FLUPROSTENOL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	L-826266	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	ENPROSTIL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	ENPROSTIL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	GR 63799	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	SC-51322	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	ILOPROST	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	CARBACYCLIN	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	ONO-AE-248	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	DG-041	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	DG-041	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	DG-041	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	ILOPROST	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	L-826266	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	L-826266	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	CLOPROSTENOL	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	CICAPROST	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	DG-041	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	MISOPROSTOL	agonist	DrugBank	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	BIMATOPROST	n/a	TdgClinicalTrial	druggable genome,g protein coupled receptor,nuclear hormone receptor
PTGER3	MISOPROSTOL	agonist	ChEMBL	druggable genome,g protein coupled receptor,nuclear hormone receptor
CXCR4	MSX-122	antagonist	TTD	cell surface,druggable genome,g protein coupled receptor
CXCR4	ALX40-4C	n/a	GuideToPharmacologyInteractions	cell surface,druggable genome,g protein coupled receptor
CXCR4	PLERIXAFOR	n/a	GuideToPharmacologyInteractions	cell surface,druggable genome,g protein coupled receptor
CXCR4	PLERIXAFOR	n/a	TEND	cell surface,druggable genome,g protein coupled receptor
CXCR4	PLERIXAFOR	antagonist	DrugBank	cell surface,druggable genome,g protein coupled receptor
CXCR4	AMD-070	n/a	DrugBank	cell surface,druggable genome,g protein coupled receptor
CXCR4	PLERIXAFOR	n/a	TdgClinicalTrial	cell surface,druggable genome,g protein coupled receptor
CXCR4	AMD-070	n/a	TdgClinicalTrial	cell surface,druggable genome,g protein coupled receptor
CXCR4	PLERIXAFOR	partial agonist	ChEMBL	cell surface,druggable genome,g protein coupled receptor
CXCR4	DOCETAXEL	n/a	CIViC	cell surface,druggable genome,g protein coupled receptor
CXCR4	MSX-122	antagonist	TTD	cell surface,druggable genome,g protein coupled receptor
CXCR4	ALX40-4C	n/a	GuideToPharmacologyInteractions	cell surface,druggable genome,g protein coupled receptor
CXCR4	PLERIXAFOR	n/a	GuideToPharmacologyInteractions	cell surface,druggable genome,g protein coupled receptor
CXCR4	PLERIXAFOR	n/a	TEND	cell surface,druggable genome,g protein coupled receptor
CXCR4	PLERIXAFOR	antagonist	DrugBank	cell surface,druggable genome,g protein coupled receptor
CXCR4	AMD-070	n/a	DrugBank	cell surface,druggable genome,g protein coupled receptor
CXCR4	PLERIXAFOR	n/a	TdgClinicalTrial	cell surface,druggable genome,g protein coupled receptor
CXCR4	AMD-070	n/a	TdgClinicalTrial	cell surface,druggable genome,g protein coupled receptor
CXCR4	PLERIXAFOR	partial agonist	ChEMBL	cell surface,druggable genome,g protein coupled receptor
CXCR4	DOCETAXEL	n/a	CIViC	cell surface,druggable genome,g protein coupled receptor
CYP4F2	PHENPROCOUMON	n/a	PharmGKB	cytochrome p450,drug metabolism,druggable genome
CYP4F2	ACENOCOUMAROL	n/a	PharmGKB	cytochrome p450,drug metabolism,druggable genome
P2RY14	UDP-GALACTOSE	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
P2RY14	UDP-GLUCURONIC ACID	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
P2RY14	PPTN	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
P2RY14	UDP-GLUCOSE	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
P2RY14	UDP-GALACTOSE	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
P2RY14	UDP-GLUCURONIC ACID	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
P2RY14	PPTN	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
P2RY14	UDP-GLUCOSE	n/a	GuideToPharmacologyInteractions	druggable genome,g protein coupled receptor
SELL	BIMOSIAMOSE	n/a	TdgClinicalTrial	cell surface,external side of plasma membrane
CDK3	RGB-286638	n/a	GuideToPharmacologyInteractions	druggable genome,kinase,serine threonine kinase,tumor suppressor
PPIC	L-PROLINE	n/a	DrugBank	druggable genome